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Head and neck squamous cell carcinoma (HNSCC) is the most frequent malignancy of the 
aerodigestive tract and the limitations in current chemotherapeutic approaches have yielded a 
poor prognosis. Synthetic double stranded (ds) RNA, which activate toll-like receptor 3 (TLR3) 
and generate interferon regulatory factor 3 (IRF3)-mediated proapoptotic responses in cancer 
cells, are being investigated as potent adjuvants to chemotherapy. We had previously shown that 
cells derived from metastatic HNSCC were unable to activate prosurvival NF-κB in response to 
TLR3 ligand, resulting in an enhanced apoptotic response compared to cells from primary 
tumors. Here, we demonstrate that in metastatic tumor-derived cell lines, transcriptional 
downregulation of receptor interacting protein kinase 1 (RIPK1), an adaptor protein of the TLR3 
pathway, enhances dsRNA-mediated apoptosis due to a loss of NF-κB activation. This is 
consistent with our observations supporting the reduction of RIPK1 expression during the tumor 
progression of HNSCC correlated with an increased promoter methylation in matched tumor 
samples from HNSCC patients. Treatment of metastatic tumor-derived cell lines with a 
hypomethylating agent rescued the expression of RIPK1, demonstrating that promoter 
methylation may be responsible for the downregulation of RIPK1. We show that silencing of 
RIPK1 enhances the tumor promoting properties in HNSCC cell lines by increasing the rate of 
migration, EGFR expression and anoikis resistance. As the downregulation of RIPK1 expression 
RIPK1 DOWN-REGULATION PROMOTES TUMOR PROGRESSION WHILE 
ENHANCING THE APOPTOTIC RESPONSE TO TLR3 LIGAND IN HEAD AND 
NECK SQUAMOUS CELL CARCINOMA  
Kevin Dylan McCormick, PhD 
University of Pittsburgh, 2016
 
 v 
contributes to the metastatic phenotype of HNSCC, but is essential for TLR3-NF-κB mediated 
pro-survival responses, we believe the results described here may open new prospects for using 
synthetic dsRNA to target metastatic tumor cells. In light of these findings, RIPK1 
downregulation as a treatment biomarker, or combinational therapies with NF-κB-signaling 
inhibitors, could be used to enhance the immunotherapeutic efficacy of synthetic dsRNA. As the 
downregulation of RIPK1 has been observed in additional carcinomas, our findings suggest that 
synthetic dsRNA could be used as a broad anti-cancer therapy and that RIPK1 expression can be 
a useful indicator to predict the therapy response.  
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1.0  INTRODUCTION 
1.1 HEAD AND NECK SQUAMOUS CELL CARCINOMA 
Carcinomas are cancers of the epithelium and account for over 80 percent of all tumor-related 
deaths worldwide (1, 2). Included in the exhaustive list of carcinomas are tumors of the 
gastrointestinal tract: the mouth, esophagus, stomach and small and large intestines, as well as 
cancers of the skin, mammary glands, pancreas, lung, liver, ovary, cervix, uterus, prostate, 
gallbladder and urinary bladder (1).  
Attributable to the accumulation of genetic events and chromosome instability from long-
term chronic exposure of the keratinocytes in the upper aerodigestive tract to tobacco and 
alcohol, squamous cell carcinoma (SCC) accounts for over 90% of head and neck cancers (3, 4). 
Specifically the exposure to the mutagens benzo[a]pyrene and nitroamines in cigarette smoke, 
that produce guanine nucleotide transversions in critical tumor suppressor genes and 
acetaldehyde, a metabolite of alcohol consumption, increase the likelihood of developing this 
disease (5). Because of the exposure to these carcinogens, HNSCC primary tumors initially 
develop throughout the upper aerodigestive tract (oral cavity, oropharynx and larynx) Figure 1. 
Additionally, human papillomavirus (HPV) has been shown to be transmitted to the oral mucosa 
during oral sex and many HNSCC tumors have been shown to be HPV E6 and E7 positive, 
leading to the assertion that HPV is also a causative agent for HNSCC (6). 
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Figure 1 Schematic overview representing the anatomical sites effected by HNSCC 
 
There are limitations in our understanding of the molecular factors that contribute to the 
multi-step tumorigenesis and tumor progression of carcinomas and HNSCC is certainly no 
exception. Because of this lack of knowledge and limitations in effective therapeutic strategies, 
over half of the patients with HNSCC die within 5 years of diagnosis (7, 8).  In addition, the 
majority of HNSCC cases are only diagnosed after the disease has metastasized to the lymph 
nodes where limitations in treatment further compound the poor prognosis (7). As a picture 
begins to emerge from research shedding light on the molecular drivers of tumorigenesis and 
tumor progression, we are beginning to develop more precise methods of treating patients 
through molecular profiling and targeted therapies (8).  
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1.1.1 Epidemiology of HNSCC 
At almost 700,000 new cases each year, HNSCC is the sixth most common malignancy 
worldwide and accounts for most tumors of the upper aerodigestive tract (7, 9–11). However, 
there are discrepancies in the incidence of HNSCC and in some countries, such as India, it 
accounts for over 60 percent of all malignancies (12). The high prevalence of HNSCC in India 
has been attributed to the risk factor of chewing areca nut or betel nut in a similar fashion of 
chewing tobacco in the US (13).  
Interestingly, the incidence of HNSCC is three fold higher in men than women and the 
median age of diagnosis is above 60 years (14). As with many other diseases in the US, there is 
an ethnic disparity in the incidence of HNSCC and the disease is twice as common in African-
Americans as their European-American counterparts (14, 15). Furthermore, European-Americans 
have an improved five year survival rate of 59.1% compared to 16.9% in African-Americans (14, 
15). Additionally, there appears to be a correlation between socioeconomic class and the 
incidence of HNSCC as individuals in a lower-class tend to be more susceptible to this disease 
(16, 17).  
 In the United States, the disease incidence appears to be decreasing over time, which is 
believed to result from a decline in the amount of smokers (18). It is intriguing that while the 
incidence of smoking related HNSCC incidence is on the decline, through smoking cessation, it 
has been reported that there is a significant increase in the amount of HPV positive HNSCC (18). 
HPV infection is the most common sexually transmitted disease in the world and, in the US 
alone, 20 million people are currently infected and 6.2 million acquire a new infection each year 
(19). Moreover, half of all sexually active Americans will be infected with genital HPV in their 
lives (19).  
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Due to the high prevalence of HPV, it is now estimated that 70-90% of newly diagnosed 
HNSCC cases in the US are HPV positive and it has been reported that HPV is found in 40-90% 
of all HNSCC cases in the developed world (20, 21). HPV positive HNSCC patients tend to be 
Caucasian, tobacco-free and are typically younger than HPV negative HNSCC patients (22). 
There is some reassurance in the fight against HNSCC as HPV positive tumors respond better to 
standard treatments and there is a more favorable prognosis in HPV positive HNSCC as the 2-5 
year survival rates are much higher in these patients (23). Moreover, with the recent advances in 
HPV vaccination it is thought that this will contribute the overall reduction in new cases.   
The majority of HNSCC cases remain undiagnosed until the disease has already 
metastasized to the cervical lymph nodes. However, there are premalignant oral lesions that have 
been associated with HNSCC including leukoplakia (white patches in the mouth that cannot be 
rubbed off) and erythroplakia (red patches that cannot be diagnosed as any other disease). 
Although both conditions are attributed to tobacco use, leukoplakia is much more common being 
present in up to five percent of the population (4). Both conditions have been shown to transform 
into HNSCC with leukoplakia progressing to malignancy in 1-3% of the cases and erythroplakia 
progressing in up to 50% of cases in 5 years (24). In addition to reducing future tumor burden, 
cessation of smoking has been shown to reduce these premalignant lesions (24). 
It has been suggested that these premalignant lesions are specifically associated with 
HPV (25). However, of the 964 leukoplakia biopsies that have been analyzed in the literature, 
only 31.1% contained HPV DNA of any type, and of the 32 cases that were diagnosed with 
erythroplakia, only 9 contained HPV 16 DNA (25). Yet, there are premalignant and benign 
tumors associated with HPV positive cancer as HPV often presents itself as warts or papillomas 
of the skin and upper respiratory tract (26). Unfortunately, in the majority of those who are 
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diagnosed with HNSCC there is no warning sign and the disease is not diagnosed until there has 
been metastasis to the lymph node resulting in a poorer prognosis (8).  
 
1.1.2 Molecular Biology of HNSCC:  
HNSCC is a heterogeneous disease, which includes three major subclasses of genetic 
classification (3). The vast majority (80%) of HNSCC is HPV negative and caused by the 
accumulation of genetic and epigenetic changes from chronic environmental exposure to 
carcinogens, most commonly to tobacco products and excessive alcohol consumption (3). The 
80% of HPV negative tumors are further differentiated into tumors with high chromosome 
instability (CIN) (65%) and low CIN (15%) presumably the immortal telomerase positive and 
mortal telomerase negative HNSCC cases respectively (4). The third etiology of HNSCC cases, 
as previously mentioned, are caused by persistent infection with HPV and together account for 
the remaining 20% (4).  However, some estimates of HPV positive HNSCC tumors are as high 
as 36% (27).  
The molecular profiling of these diseases has shown that these classes can have distinct, 
and sometimes overlapping, changes in signaling pathways and response to therapies (28). For 
example, somatic mutations in the tumor suppressor TP53 gene are found in 60-80% of HPV 
negative HNSCC, whereas TP53 is also inactivated in HPV positive HNSCC albeit through 
degradation by HPV E6 protein (discussed in detail below) (29). Similarly the retinoblastoma 
protein (Rb) pathway is often inactivated in both HPV negative and positive tumors. In addition, 
the activation of telomerase is common in 80% of HNSCC and is not specific to HPV negative 
tumors. Moreover, it has been shown that changes in growth factor signaling through epithelial 
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growth factor receptor (EGFR) expression, common in both HPV positive and negative tumors, 
negatively correlates with clinical outcomes in both cases (30). Interestingly, there is limited data 
providing an explanation of the cell manipulation caused in low CIN tumors. 
1.1.2.1 High and Low Chromosome Instability The molecular mechanisms driving tumor 
progression in HNSCC largely follow the classic cancer hallmarks as proposed by Hanahan and 
Weinburg in their well-known cancer review articles (31, 32). These hallmarks are based on 
molecular evidence that has emerged in the past 30 years, supporting the multiple hit theory of 
tumorigenesis and tumor progression.  It has long been postulated,  based on mathematical 
modeling, that there are an estimated 6 hits which drive most cancers into fully malignant 
diseases (33, 34). According to Hanahan and Weinburg the initial 6 hallmark capabilities 
acquired by a cell to become malignant are: 1) sustaining proliferative signaling, 2) evading 
growth suppressors, 3) resisting cell death, 4) inducing angiogenesis, 5) enabling replicative 
immortality and, finally, 6) activating invasion and metastasis. Interestingly, they postulated that 
although all of these hits are necessary but they may not occur in the same order.     
Sustaining proliferative signaling 
The growth of normal tissues is carefully controlled by the release and detection of growth-
promoting signals that instruct the cell to progress through the cell cycle. As such, normal cells 
are unable to proliferate without some form of stimulatory signals. Cancer cells deregulate and 
often circumvent these signals in order to proliferate independently of this homeostatic 
regulation.  
Enhanced expression of cell surface receptors, which sense proliferative signals, are often 
responsible for the sustained stimulation needed for cancer cells to grow (29).  The enhanced 
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expression of growth receptors facilitate the cells in becoming hyper-responsive to ambient 
levels of growth factors present within the tumor site. As previously mentioned, EGFR initiates 
one such pro-growth signaling pathway that appears to be crucial in driving proliferative signals 
in HNSCC and thus, EGFR is overexpressed in 80% of cases (35–37). EGFR is a receptor 
tyrosine kinase that signals through the Ras-MAPK, phospholipase C and PI3K-PTEN-AKT and 
mTOR pathways to induce proliferation, survival and protein translation. It is therefore 
unsurprising that in addition to the overexpression of EGFR, there are often mutations in the 
downstream mediators of this pathway, including mutations leading to constitutively active PI3K 
and AKT or defective PTEN (29).  
Evasion of Growth Suppressors 
In addition to deregulating the homeostatic control of proliferative signaling, cancer cells must 
evade growth suppressors. This is accomplished by preventing anti-proliferative signals, which 
act to block the advancement through the G1 phase of the cell cycle, from acting on the cell. In 
the case of HNSCC, it appears that the transforming growth factor-β (TGFβ) pathway is one of 
the most important suppressors of cell growth, and thus the TGFβ receptor and downstream 
Smad proteins are often downregulated or mutated in HNSCC (38).  
After binding to the TGFβ binding type II receptor (TRII), TGFβ signaling is activated by 
the formation of a heterotetrameric complex composed of a TRII dimer and a dimer of the 
signaling type I receptor (TRI) (39, 40). This serine/threonine kinase receptor complex then 
recruits the downstream Smad proteins and, after R-Smad is phosphorylated by TRII, they form 
heterodimers and homodimers and translocate into the nucleus. This leads to the induction of 
genes that enhance apoptosis and limit cell proliferation, such as the cell-cycle inhibitors like 
cyclin-dependent kinase inhibitors CDKN2B, CDKN1A and CDKN1C (39, 41). These factors are 
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responsible for blocking the cyclin:CDK complexes that facilitate the initiation of cell cycle 
progression by phosphorylating pRb and triggering its release from the E2F transcription factors.  
Interestingly, in addition to enhancing apoptotic signaling and inhibiting progression into 
the cell cycle, it has also been shown that TGFβ signaling may also down-regulate the expression 
of hTERT through Smad3 negative regulation (39). This suggests that the loss of the TGFβ 
signaling in cancer cells may not only contribute to the evasion of growth suppression, but also 
in the immortalization of cancer cells (discussed in more detail below) (39, 42, 43). Additionally, 
as previously mentioned, loss of TGFβ alters the phosphorylation patterns of downstream pRb. 
However, the homeostatic function of pRb is often perturbed in HNSCC, suggesting that there 
are overlapping patterns in evading growth suppressing signals (discussed in more detail below). 
Evading cell death 
Disruption of the normal homeostatic control of cell growth and death by genetic, metabolic and 
signaling aberrations is a hallmark of tumorigenesis (44, 45). There are several mechanisms that 
elicit cell death including, caspase dependent intrinsic (internal crisis signals) and extrinsic 
apoptosis (death receptor signals), anoikis (loss of attachment), necrosis, necroptosis (i.e. 
programmed necrosis differentiated from physical or chemical “accidental” injury induced 
necrosis), pyroptosis (inflammasome mediated caspase-1-dependent cell death), autophagic cell 
death, mitotic catastrophe etc. (46–48). Fortunately, many oncogenic events that promote tumor 
development also increase the sensitivity of cells to death inducing stimuli including 
chemotherapeutic drugs (44). The apoptotic and necroptotic pathways are the major cell viability 
regulators, and the activation or restoration of these pathways offers potential therapeutic targets 
to induce tumor cell death (46).  
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In the past, the characterization of in vitro cell death has been largely based on 
morphological characteristics, i.e. apoptosis leads to DNA fragmentation and membrane 
blebbing, whereas necrosis is characterized by swelling of the endoplasmic reticulum, 
mitochondria and cytoplasm, leading to rupture of the cell membrane (48). However, deeper 
insights into the molecular pathways that regulate cell death have led to more precise and 
quantitative biochemical techniques. Nevertheless, there are still overlapping molecular 
mechanisms in cell death and thus, there has been exhaustive work to extrapolate biochemical 
techniques to differentiate a particular cell death pathway (48). In fact, as more molecular 
mechanisms have been elucidated, the number of cell death pathways has continued to increase.    
Apoptosis is a programmed cell death pathway that exists as a quality control mechanism 
to eliminate cells that are no longer needed or that present a potential threat to the body such as 
infected or cancerous cells (49). Although apoptosis can be initiated by either external or internal 
signals, both pathways converge and initiate the intracellular proteolytic cascade mediated by 
caspases (caspases may also mediate pro-inflammatory signaling in addition to apoptosis). 
Caspases are a family of proteases which have a cysteine at their active site and act to cleave 
specific target proteins at aspartic acids (50). The caspase proteins exist as inactive procaspases, 
which are activated by proteolytic self-cleavage (50).  
 Extrinsic apoptosis can be initiated through activation of a number of extracellular 
signals including, growth/survival factor depletion, hypoxia, radiation and loss of cell-matrix 
interactions (50). Additionally, there are external cell receptors harboring a death domain that 
activate apoptosis such as the Fas and TNF receptor. Upon ligand binding, these receptors recruit 
a number of intracellular adaptor proteins (most vital to the process is FADD) that recruits and 
triggers the formation of initiator procaspase-8, forming a death-inducing signaling complex 
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(DISC), which in turn activates down-stream executioner caspases (reviewed in sections below) 
(51).  
Likewise, in intrinsic apoptosis, there are several internal signals which can activate 
initiating caspases including, DNA damage (produced by cell-cycle checkpoint defects or 
exogenous toxins), telomere malfunction and inappropriate proliferative signals produced by 
oncogenic mutations (52). The intrinsic form of apoptosis is also known as mitochondrial 
apoptosis because it depends on factors released from the mitochondria such as cytochrome c, 
which is released in response to signals mediated by the activity of the Bcl-2 family of proteins, 
dictated by the balance of pro-apoptotic (Bax, Bak, Bid, Bim) or anti-apoptotic (Bcl-2, Bcl-XL, 
Bcl-W) factors (32).  
After cleavage and activation, the extrinsic and intrinsic initiator caspases will cleave the 
executioner procaspases 3, 6 and 7 (51). These executioner caspases then cleave several proteins, 
an act that yields one of three of the following outcomes: (1) destroying the protein’s activity, (2) 
triggering its activity by removing inhibitory domains or (3) creating a dominant–negative form 
of the protein. These cleaved proteins then directly contribute to the apoptotic state where 
cellular membranes are disrupted, the cytoplasmic and nuclear skeletons are broken down, the 
cytosol is extruded, the chromosomes are degraded, and the nucleus is fragmented (32). 
A number of genes and proteins are deregulated in HNSCC, which act to either enhance 
cell survival signals or directly inhibit the apoptosis pathway. For example p53, one of the 
master initiators for apoptosis, is often mutated or down-regulated in HNSCC. Additionally, the 
PI3K-AKT pathway triggers the inactivation of pro-apoptotic molecules such as BAD and 
caspase-9 by phosphorylation. In addition to the PI3K and AKT proteins being over-expressed, 
and sometimes constitutively activated, PTEN, the phosphatase that removes phosphate groups 
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from PI3K, is often lost or mutated in HNSCC (29). Moreover, the external death ligand 
induction of apoptosis can be suppressed through the over-expression of the FLICE-inhibitory 
protein (FLIP), which interferes with caspase 8 activation (53, 54).    
Necroptosis morphologically resembles necrosis (unregulated cell death), but is a 
regulated active type of cell death that requires many of the same signals, both intrinsic and 
extrinsic, as apoptosis; however, it occurs under conditions of caspase inhibition. Necroptosis is 
differentiated from apoptosis by morphological changes, as characterized by swelling of the 
endoplasmic reticulum, mitochondria and the cytoplasm, which results in the rupture of the 
cellular membrane.  
The best characterized initiators of necroptosis are those downstream mechanisms of 
death domain receptor ligands including TNF, though, more recent evidence suggests that the 
Toll-like receptors 3 and 4 can trigger this form of cell death (these pathways are discussed in 
detail below). In short, the death domain receptor recruits the protein kinase RIPK1 which, after 
being polyubiquitinated, activates the pro-inflammatory NF-κB signaling and the downstream 
execution of either apoptosis or necroptosis. Polyubiquitinated RIPK1 can interact with RIPK3, 
resulting in the phosphorylation of MLKL and its downstream lysis of the cellular membrane 
(55). A similar mechanism exists in the NF-kB signaling, TLR3 and TLR4 pathways, though 
there are differences in the activity of the RIPK1 kinase domain (as described in sections below). 
Because of its capacity to induce cell death, TNF was thus one of the first molecules to be 
demonstrated to induce hemorrhagic necroptosis in cancer cells. Unfortunately, because TNF 
elicits a strong inflammatory response and thus yielding a high level of toxicity, TNF did not 
fulfill expectations to be useful in treating tumor cells (56, 57).  
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Inducing angiogenesis 
Tumors are able to alter energy metabolism and often use the glycolysis pathway, even in the 
presence of oxygen, in order to grow more than a few millimeters. Tumors must therefore recruit 
blood vessels for the delivery of nutrients and oxygen supply to compensate for the loss of ATP 
during glycolysis as well as to dispose of catabolites (29, 31, 58, 59). In the case of HNSCC as 
with other tumors neo-angiogenesis is accomplished by the overproduction of pro-angiogenic 
factors. The most potent of these factors secreted by HNSCC cancer cells for the recruitment of 
new blood vessels is vascular endothelial growth factor (VEGF) and therefore this factor has 
been shown to be up-regulated in most HNSCC cases (60).  
The close proximity of these newly established blood vessels within the tumor presents a 
new opportunity for growth advantage through nutrient and oxygen delivery and also a potential 
avenue for the dissemination of the mutant cells from the primary site to metastasis. It is 
therefore unsurprising that this factor is considered a hallmark of tumorigenesis and progression 
as VEGF is associated with the prognosis of HNSCC including disease outcome and associated 
with increased rates of metastasis (61, 62).    
Limitless Replication potential: enabling replicative immortality 
Due to DNA damage incurred over time and shortening of telomeric DNA through cell 
proliferation, differentiated squamous cells have a limited replication potential and are not 
immortal. The first obstacle that a cell must overcome is senescence by deregulating the 
checkpoint proteins in the p53 and pRb pathways. It is unsurprising therefore that TP53 
mutations are found in 60-80% of all HNSCC cases and the majority of WT TP53 cases are HPV 
E7 positive (29, 63). The pRb pathway is also perturbed, usually by mutations in p16INK4A 
(CDKN2A), cyclin D1 (CCND1) or with the expression of HPV E6 (29). Additionally, as with 
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most cancers, to prevent senescence and crisis induced by telomere shortening, telomerase 
activity is detectable in 80% of HNSCC cases analyzed and it has been suggested that the 
remaining 20% most likely undergo the TERT independent process of telomere lengthening or 
alternative lengthening of telomeres (ALT) (64–66). 
Activating Invasion and Metastasis: HNSCC EMT and Lymph Node Metastasis 
Metastasis is the process of the dissemination of cancerous cells from the primary tumor site to 
distal organs (67). At the time of diagnosis, the majority of HNSCC patients will exhibit 
locoregional or distal metastasis, primarily to the cervical lymph nodes and as with many other 
cancers due to this late stage diagnosis of HNSCC, metastasis correlates with poor survival rates 
(68). Invasion of HNSCC into distal tissues is a complex multistep process where chemotactic 
responses drive the migration of cells first into the basement membrane, through the extracellular 
matrix (ECM), into regional vasculature, followed by extravasation at the metastatic site (68). In 
addition, even after traversing the extracellular matrix, the cancerous cells must survive in 
circulation in either the blood or lymphatic systems, before and after reaching the lymph nodes.  
This passage of metastasis begins with the process known as the epithelial-mesenchymal 
transition wherein cancerous cells acquire the phenotypes of mesenchymal cells such as 
fibroblasts (1). During this process, tumor cells alter their epithelial characteristics including loss 
of cytokeratin, tight junctions, polarity and acquire new phenotypic changes including a 
fibroblast shape, motility and invasiveness, increased resistance to apoptosis and anoikis, 
protease secretion, fibronectin secretion and, most vital to EMT, the loss E-cadherin expression 
with gain of the mesenchymal adherens junction protein, N-cadherin (1).   
The first barrier HNSCC tumor cells must surmount to break away from the primary site 
and migrate into distant tissues is the basement membrane and the ECM (68). The ECM is an 
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intricate network of macromolecules, comprised primarily of proteins and polysaccharides, 
structured into a meshwork that fills the extracellular space within tissues and largely determines 
the tissues physical properties (69). The components of the ECM are mainly produced locally by 
cells within the matrix such as fibroblasts. The two main classes that encompass the ECM are, 
polysaccharide chains called glycosaminoglycans (GAGs), that are covalently linked to proteins 
(proteoglycans), which include: collagen, elastin, fibronectin and laminin (69). The collagens 
make up the majority of the components of the ECM and are the most abundant proteins in 
animals, constituting 25% of the total protein mass (1).     
  Migration through these sites requires the proteolytic degradation of the ECM 
components by actin polymerization driven subcellular structures, termed invadopodia, that 
mimic the normal podosomes of macrophages, osteoclasts and smooth muscle cells (68). The 
invadopodia are comprised of a central filamentous (F)-actin core that is regulated by a number 
of assembly molecules including those of the Arp2/3 complex (70). They are enriched with a 
number of migration factors including actin regulatory proteins, adhesion molecules, signaling 
proteins and remodeling proteins, but the most important factor localized to the invadopodia, that 
facilitate traversing through the basement membrane and excavate passageways in the ECM, are 
the matrix metalloproteases (MMPs) (Table 1). MMPs are zinc-dependent metalloproteases that 
are synthesized as latent enzymes and are later activated by the release of propeptide domains 
(71). Once activated, the MMPs cleave ECM components such as collagen, proteoglycans and 
glycoproteins. Interestingly, in addition to the secretion of MMPs by neoplastic epithelial cells, 
the cancerous cells often rely on the recruitment of stromal cells such as macrophage, mast and 
fibroblast cells, which will aid in the secretion of these MMPs (71).   
 
15 
Table 1 HNSCC Related Matrix Metalloproteinases and Their Extracellular Matrix Substrates 
Name of MMP Alternative Name of 
MMP 
Expression Major ECM 
Substrate 
MMP-1 Collagenase-1 Fibroblasts>tumor 
cells, macrophages 
and endothelial 
cells 
Fibrillar collagens 
MMP-2 Gelatinase Fibroblasts>tumor 
cells and 
macrophages 
Collagen IV, 
denatured collagens 
MMP-3 Stromelysin-1 Fibroblasts>tumor 
cells, macrophages 
and endothelial 
cells 
Proteoglycans, 
glycoproteins 
(laminin, fibronectin, 
vitronectin) 
MMP-7 Matrilysin Fibroblasts and 
macrophages 
Similar to MMP-3 
MMP-9 Gelatinase B Fibroblasts and 
endothelial cells 
Similar to MMP-2 
MMP12 Metalloelastase Fibroblasts and 
tumor cells 
Elastin 
MMP-14 MT1-MMP Fibroblasts and 
tumor cells 
Fibrillar collagens, 
gelatins 
Note: Table 1 Adapted from Rosenthal et al and Robert Weinburg's The Biology of Cancer (1, 71) 
  
Of the MMPs overexpressed in carcinomas, MT1-MMP appears to be the most critical 
enzyme in degrading the ECM (71). Unsurprisingly therefore, it has been shown that MT1-MMP 
is overexpressed in HNSCC and that the expression profile is upregulated by aberrant growth 
factor signaling, most notably EGFR and MET proto-oncogene receptor tyrosine kinase (cMET) 
signaling pathways that are known to be over activated in HNSCC either by mutation or 
overexpression (72–74). MT1-MMP unlike the other MMPs, is not secreted by cells, but rather, 
is cleaved intracellularlly by the proprotein convertase furin, which is also overexpressed in 
HNSCC, and then expressed on the cell surface as an active protease (71, 75, 76). MT1-MMP is 
also produced by stromal cells that can become activated in the presence of invading cells in the 
ECM. 
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1.1.2.2 The Human Papilloma Virus In addition to HNSCC caused by exposure to 
environmental carcinogens, it has also been associated with HPV infection. Hundreds of HPV 
genomes have been sequenced to date and there have been 148 types identified to infect humans. 
Almost 33% of HPV types have been associated with HNSCC and cervical cancer. These  types 
are further characterized by high- and low- associated cancer risk including the high-risk types: 
16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82 and low-risk infections 
including 6; 11; 40; 42; 54; 55; 61; 62; 64; 67; 69; 70; 71; 72; 81; and 82 subtype IS39, 83, 84, 
and 89 (cp6108) (77). 
HPV are small (52-55nm), circular dsDNA (group I), nonenveloped viruses belonging to 
the Papillomaviridae family. There are eight open reading frames in the HPV genome encoding 
for three functional components known as the early (E) region, the late (L) region and long 
control region (LCR) (25). The E region codes for proteins that are essential for replication, 
associated with cellular transformation and for the control of viral transcription, while the L 
encodes for the L1 and L2 structural proteins that make up the viral capsid. Finally the LCR is 
responsible for viral replication and virus gene transcription (26, 78).  
The cancerous nature of HPV can be directly attributed to its manipulation of the factors 
governing cell cycle checkpoints during its productive replication cycle. HPV is host-specific 
and tissue specific, infecting the basal transitory-amplifying cells of the epithelium. After the 
entry into these cells, presumably through damage of the upper-epithelium layers, the HPV 
genomes are established as extrachromosomal elements in the nucleus and the copy number of 
the genome is amplified 50-100 times per cell (78). During cell division the genome is 
distributed between the daughter cells and as these daughter cells differentiate into the upper 
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squamous layers, the initially infected basal cell continues to be a reservoir for further cell 
divisions.  
Because the virus in the infected basal cells is not actively producing viral progeny, the 
cells at this stage are not lysed by the virus and continue to proliferate, allowing the virus to 
persist in this layer of cells for periods as long as years. Since HPV rely on cellular enzymes to 
replicate their genome, as the infected daughter cells exit the cell cycle and begin to differentiate, 
the HPV encoded proteins must act to inhibit the blockage of the complete cell cycle exit and 
induce S-phase. This is principally accomplished, at least in high cancer risk HPV infectious 
cycles, through the modulation of pRb and p53 checkpoint proteins, by the virally encoded 
proteins E6 and E7, respectively (79–82). As previously mentioned, the HPV types that are 
attributed to these cancers can be classified as either high- or low-risk risk viruses, dependent on 
the capability of the viral E7 protein to bind with p53 and thus induce its degradation. In 
carcinomas, it has been shown that the whole viral genome or fragments thereof are integrated 
into the chromosomal DNA of expanding cells (83, 84).  The integration of the viral genome into 
cells facilitates the constitutive expression of the genes E6 and E7 and the persistent deregulation 
of the cell cycle.    
1.1.3 Current treatments for HNSCC:  
The treatment regimen of HNSCC varies depending on diagnosis, with approximately 40 percent 
of patients undergoing surgical resection (85, 86). For those with unresectable tumors, 
concurrent chemoradiotherapy (CRT), i.e. radiation combined with cisplatin-chemotherapy, (a 
platinum based drug that binds to and causes crosslinking of DNA and thus induces apoptosis in 
cells), is recommended (8). Unfortunately, a meta-analysis of 87 trials recently revealed that the 
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survival benefit for chemotherapy is only 4.5% for a five year period and only slightly higher for 
concurrent chemotherapy at 6.5% (87, 88). In addition to cisplatin, there have been additional 
potential HNSCC chemotherapeutics that have made it into clinical trials including the mitotic 
inhibitors (taxanes) however, there was no significant benefit over the use of cisplatin and 
therefore little progress has been made to find better therapeutics for treating HNSCC (87).  
As elevated EGFR expression has been associated with most HNSCC an EGFR 
monoclonal antibody, cetuximab, is the single exception for novel HNSCC therapy treatments to 
emerge and can be used either in second-line therapy after failure of platinum-based 
chemotherapy or in first-line therapy in combination with platinum-based chemotherapy (8). 
Unfortunately, it has been shown that treatment with combined cetuximab and cisplatin only 
improves the five year median survival of HNSCC patients by a medium of two months, 
compared to monotherapy (89, 90). However, a similar study found the survival rate for 
cotreatment with cetuximab and radiotherapy improved the five year survival rate to 49 months 
compared to 29 months for radiation alone (30, 91).  
In addition to cetuximab, additional EGFR downstream mechanisms have been targeted. 
The cytoplasmic tyrosine kinase of EGFR has been targeted in clinical trial with a number of 
small molecule kinase inhibitors such as gefitinib, erlotinib or lapatinib, although, due to limited 
efficacy, these therapies have not been FDA approved for the treatment of HNSCC (30). Unlike 
cancers such as non-small cell lung cancer, where EGFR is often mutated and therefore these 
tyrosine kinase inhibitors are much more effective, EGFR is seldom mutated in HNSCC and is 
rather overexpressed, making resistance to EGFR inhibitors common due to the activation of 
downstream pathways (30). Nevertheless, there have been attempts to target the downstream 
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pathways including PIK3-Akt signaling, with a number of combined and pan-class inhibitors, 
however none have yet to succeed in clinical trials (30).  
Recently it was shown that, in addition to EGFR, MET levels are also elevated in the 
majority of HNSCC and that treating HNSCC cell lines with MET inhibitors yielded more 
additive cell death effects when combined with cisplatin or the EGFR tyrosine kinase inhibitor 
erlotinib treatments (92). However, no clinical trials of MET inhibitors have been conducted to 
date. Because of their critical roles in the metastasis of carcinomas, several MMP inhibitors have 
been taken to Phase III clinical trials, however none of them have been tested on HNSCC and 
overall they have been found to have limited clinical benefit (71, 93, 94). Nevertheless, because 
of a lack of efficacy of these therapies, of the almost 500,000 new cases that develop each year 
over 300,000 cases result in death (8, 12). 
Molecular profiling of select patient populations, who are physiologically more 
susceptible to certain chemotherapies and immunotherapies, (predictive biomarkers) is offering 
novel strategies for treating HNSCC. These predictive biomarkers are being investigated to 
overcome the limitation in current treatments and also to develop new drugs for the improved 
therapeutic agents in oncology (95). Among the novel predictive biomarkers including EGFR 
and MET mentioned above, TLR3 expression has been shown to positively correlate with the 
efficacy of synthetic dsRNA (poly(I):poly(C)) to eliminate cancer cells (95, 96). Though, in 
addition to causing growth arrest and apoptosis in cancer cells, TLR signaling has been shown to 
induce pro-inflammatory responses and therefore its application for targeted immunotherapy has 
not yet proven effective. To improve the efficacy of poly(I):poly(C) as an adjuvant, additional 
factors contributing to these discrepancies need to be addressed. 
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1.2 HNSCC IMMUNOSURVEILLANCE AND IMMUNOEDITING:  
In addition to the 6 canonical hallmark mechanisms required for a cell to become malignant (as 
described above), avoiding immunosurveillance presents an additional challenge for tumors and 
is widely accepted as the 7th hallmark of cancer (97, 98). The theory of cancer 
immunosurveillance predicts that the innate and adaptive immune systems work together to 
detect the presence of a developing tumor and, in most cases, destroy these precursors before 
they become clinically apparent (98). However, emerging evidence suggests that cancer 
immunosurveillance represents only one step of a broader process, termed cancer 
immunoediting, whereby a developing tumor must proceed sequentially through three distinct 
phases termed elimination, equilibrium and escape (99).  This model stresses the dual host-
protective versus tumor-sculpting actions of the immune system in cancer (97, 99).  
The basis of cancer immunosurveillance, or tumor “elimination,” is that cancer cells 
express antigens (neoantigens) that differentiate them from their nontransformed counterparts 
(97). These neoantigens are released, through means such as necroptosis, and captured by 
dendritic cells (DCs) for antigen processing (100).  The activated DCs then function as antigen 
presenting cells (APCs) whereby they present the captured neoantigens on HLA class I and HLA 
class II molecules to T cells (100). This presentation drives the priming and activation of 
cytolytic T lymphocytes (CD8+T cells) that function to eliminate premalignant cells presenting 
the neoantigen by HLA class I (100, 101). The magnitude of the immune response is determined 
at APC stage, with a critical balance representing the ratio of T effector cells versus T regulatory 
cells being vital to the final outcome (100). Also contributing to the elimination process, are 
natural killer cells (NK cells) that work in concert with CD8+ T cells to kill cells that no longer 
express self-antigens or express stress-signaling proteins (100).  
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For an effective anticancer T cell response, the priming of T cells must be accompanied 
by immunogenic signals including numerous cytokines, chemokines and additional cellular 
factors that are released by tumor cells (100). Thus the immunologic rejection of a developing 
tumor likely requires an integrated response involving both the innate and adaptive arms of the 
immune system (99). However, the precise mechanism in which the immune system is alerted to 
the presence of neoantigen in a developing tumor has not been completely elucidated (100). It is 
thought stress-associated or damage-associated molecular patterns (DAMPs) from the innate 
immune activation, and bridge the generation of adaptive immunity (102). Of these signals, the 
interferons (IFNs), both type I (IFN-α/β) and type II (IFN-γ), have emerged as critical 
components of the cancer elimination process, and work is ongoing to define their respective 
roles in promoting antitumor immune responses (103, 104). 
The essential role of IFN-γ in cancer elimination is well-documented in vivo  (103, 105–
107).  It has been shown that IFN-γ receptor (IFNGR1) knockout mice, tumor cells with 
dominant-negative IFNGR1 mutations, and tumor cells treated with IFN-γ-neutralizing 
antibodies have all been shown to have compromised tumor rejection (103, 105–107). IFNGR1 
is expressed on nearly all cells and IFN-γ signaling causes an exhaustive list of cellular effects in 
both innate and adaptive immune cells as well as tumor cells, which is discussed in detail in a 
comprehensive review by Schroder and colleges (105). However, because of the cross-talk and 
overlapping function of the Type I (IFNα/β) and II IFNs, several studies have recently emerged 
demonstrating the essential roles IFNα/β. For example, both type I and II IFN up-regulate HLA 
class I presentation to enhance the quality and diversity of antigen that is presented to CD8+ T 
cells. IFNα/β have been shown to play a central role in the process of immunoediting by 
enhancing the maturation, co-stimulatory activity and by increasing the capacity of dendritic 
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cells to present neoantigens (104). Additionally, it was shown that Type I IFN signaling caused 
the release of chemokine (C-X-C motif) ligand 10 (CXCL10), which is a potent chemo-attractant 
for adaptive and innate immune cells (108).  
In the equilibrium phase of the immunoediting process, rare tumor variants begin to 
survive the elimination process (109).  In this phase the adaptive immune system prevents tumor 
cell outgrowth and also begins to sculpt the immunogenicity of the cancerous cells (109). Thus, 
in the equilibrium phase, the immune system maintains the tumor cells in a state of dormancy 
(110).  Tumor antigens are either no longer detected or recognized as “self” by DCs and T cells 
in the equilibrium phase, thereby creating T regulatory cell responses rather than effector 
responses (111). Moreover, the elimination of a tumor in this phase is restricted by a deficiency 
of infiltrating effector T cells and by suppressive factors present in the tumor microenvironment 
that cause effector T cells to become exhausted (111). 
In the final step of tumor immunoediting, tumor cells escape immunosurveillance. This 
phase occurs following the selection of the tumor cells that are more fit to survive after the 
immuneselection or by establishing conditions within the tumor microenvironment that facilitate 
tumor outgrowth (109). There are multiple ways by which tumor cells can escape 
immunosurveillance. In addition to secreting factors that lead to induction of a Th2 
proinflammatory response over Th1 T cell response, HNSCC tumors are able to escape immune 
destruction by concealing the presentation of irregular proteins that should be recognized as 
neoantigens by the adaptive immune system (112). One of the well-established mechanisms 
whereby cells evade elimination by the adaptive immune system is through the loss of HLA I 
antigen presentation. HLA class I expression has been shown to be down-regulated in 
approximately 50% of HNSCC cases and has been associated with lymph node metastasis (113–
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115). This was shown to be caused by a loss of HLA components such as HLA heavy chain and 
beta2-microglobulin (β2m) that form the class I-β2m-antigen complex (113–115). 
In addition to evading interferon signaling and exhausting the CTL and NK cells, 
deregulated innate immune signals can contribute to a cancer promoting tumor 
microenvironment (112). Of the innate immune pathways correlated with tumor progression of 
HNSCC, up-regulated activity of NF-κB, and the downstream cytokines and chemokines that 
promote growth and recruit pro-inflammatory cells, has been shown to be important for evading 
immune destruction of the tumor (112, 116). The pro-inflammatory cytokines and chemokines, 
interleukin (IL)-1, IL-6, granulocyte/monocyte-colony stimulating factor (GM-CSF) and 
chemokine CXCL1 have been shown to contribute to tumor progression in a number of models 
including HNSCC (112, 116–118). Secretion of these factors results in a potent proinflammatory 
response that leads to enhanced myeloid and monocyte leukocyte infiltration and thus, a more 
pronounced Th2 dominant pattern with increased IL-2, IL-12, IFNγ and tumor necrosis factor α 
(TNFα) and elevated IL-4 and TGFβ (117, 118). The presence of Th2 T cells leads to a more 
robust inflammatory response and a downregulation of the recruitment and activation of CTL 
cells (100).  
 
1.2.1 Innate Immune Signaling in HNSCC 
Mammalian cells possess surveillance sensors known as pattern recognition receptors (PRR) 
used for the detection of pathogen associated molecular patterns (PAMPs) derived from invading 
pathogens and damage-associated molecular patterns (DAMPs), in both extracellular and 
intracellular environments (119). These sensors initiate both the innate immune response and 
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later, prime the adaptive immune response required to eliminate the invading pathogen or 
damaged cells. There are four major groups of PRRs categorized by their structural features; 
Toll-like receptors (TLRs), retinoic acid-inducible gene I-like receptors (RLRs), nucleotide-
binding oligomerization domain-like receptors (NLRs), and C-type lectin receptors (CLRs) 
(120).  
TLRs recognize numerous conserved PAMPs including the nucleic acids dsRNA 
(TLR3), ssRNA (TLR7 and 8), ssDNA (TLR9) and the pathogen ligands bacterial 
lipopolysaccharides (TLR4), flagellin (TLR5) and lipopeptides (TLR2-TLR1, 6 or10), whereas 
RLR are only found in the cytoplasm and are RNA helicases that recognize nucleic acids (121). 
Also in the cytoplasm of cells are the NLRs that recognize several DAMPs and PAMPS 
including nucleic acids, changes in ion concentration, microbial peptides (including toxins) and 
polysaccharides, reactive oxygen species etc. The NLRs form inflammasomes that work in 
concert with the TLR and RLRs by activating the secretion of downstream pro-inflammatory 
cytokines via caspase-1 activation (122).   
Activation of the TLR receptors, by PAMP or DAMP binding, initiates a signaling 
cascade which leads to the induction of both IFN and proinflammatory cytokines (121). The 
induced IFN is secreted and, upon binding to IFN receptors, stimulates the phosphorylation of 
JAK-STAT signaling that leads to the production of IFN-stimulated genes (ISGs) and thus the 
establishment of an anti-viral and –microbial state (121). Because the activation of these 
receptors results in the induction of a robust immune response, there has been an interest in 
utilizing ligands for these sensors to eliminate cancer cells directly, through apoptosis, or through 
priming the adaptive immune response favor of the CTL activation (109).  
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The TLRs are class I transmembrane glycoproteins and are characterized by extracellular 
domains containing a varying number of leucine-rich-repeat (LRR) motifs (123).  These LRR 
motifs are involved in protein-protein interactions and ligand recognition. TLRs also contain a 
single transmembrane α-helix and a conserved cytoplasmic domain containing a Toll/interleukin-
1 receptor (TIR) domain, which is involved in signaling adaptor recruitment (124). In humans 
there are a 10 TLRs (TLR1-10) that differ in their subcellular localization, ligand specificity, 
downstream signaling adaptors, and in the cellular responses they induce (Figure 2) (124).  
Based on subcellular localization the TLRs can be divided into two groups. The 
heterodimers of TLR2–TLR1, TLR2-TLR6 or TLR2–TLR10 and homodimers of TLR5 and 
TLR4 bind to their respective ligands at the cell surface, whereas TLR3, TLR7–TLR8, and 
TLR9 localize to the endosomes and sense nucleic acids  (123). However, TLR4 is an exception 
to this localization pattern as it may sense LPS at the cell surface as well as in endosomes (123).  
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Figure 2 Detailed schematic of human toll-like receptor signaling: Homodimers of TLR4, TLR5 and 
heterodimers of TLR2 and TLR1, TLR6 or TLR10 sense their respective ligands at the cell surface. Following this, 
the TIR domains of these TLRs recruit the adapter MyD88 either directly (TLR5) or via the recruitment of the 
adapter MAL (TLR4 and TLR2). The recruitment of MyD88 at the cell surface leads to a downstream signaling 
cascade and the activation of pro-inflammatory cytokines. Similarly, homodimers of TLR3, TLR4, TLR9 and 
heterodimers of TLR7 and TLR8 sense nucleic acids in endosomal compartments. TLR7-TLR8 and TLR9 recruit 
MyD88, whereas TLR3 and TLR4 signal through a unique adaptor, TRIF, causing the activation of pro-
inflammatory cytokines as well as Type I IFN. Figure adapted from O’Neill et al. (123) 
 
 
Upon ligand binding, the TLRs activate downstream signaling pathways by recruiting 
either of the two adaptor molecules TIR domain-containing adaptor (TRIF, also known as 
TICAM-1) or myeloid differentiation primary response gene 88 (MyD88) (121). Each of the 
TLRs signal through Myd88 with the exception of TLR3, which exclusively recruits TRIF, as 
discussed in detail below (121, 125).  In addition to its dual signaling at the cell surface as well 
as in endosomes, activated TLR4 is able to recruit the adaptors MYD88-adaptor-like protein 
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(MAL) and TRIF-related adaptor molecule (TRAM), which facilitate the interaction of TLR4 
with both MyD88 and TRIF respectively (123).  
The engagement of TRIF and MyD88 with the activated TLR receptor stimulates the 
downstream signaling pathways, which involve the recruitment of the adaptor molecules TNF 
receptor-associated factors (TRAFs) and IL-1R-associated kinases (IRAKs) (123).  This 
interaction causes the activation of the mitogen-activated protein kinases (MAPKs) JUN N-
terminal kinase (JUN) and p38 and to the activation of transcription factors (123). These 
transcription factors induce the production of pro-inflammatory cytokines (via cAMP response 
element-binding protein (CREB), activating protein-1 (AP-1) and NF-κB activation) and type I 
IFN and ISG (through IRF3 and IRF7 activation) leading to the anti-viral and –microbial state.  
Although TRIF and MyD88 recruitment drives the activation of NF-κB and IRF, it is thought 
that MyD88 signaling causes a more pronounced NF-kB pro-inflammatory response, while TRIF 
signaling leads to a more enhanced IRF3 activation (121).   
1.2.2 Toll-like Receptor Protein (TLR3): 
TLR3 is made up of an N terminal ectodomain (ECD) formed by 23 LRRs, a transmembrane 
domain spanning the endosomal membrane and a C terminal TIR domain (126, 127). Viral 
dsRNA is recognized by TLR3 through the ECD in endosomes of cells, which induces TLR3 to 
dimerize and recruit the adaptor protein TRIF (Figure 3) (128–130). Upon recruitment, TRIF 
oligomerizes and activates two divergent pathways leading to the activation of IRF3 through its 
N terminal TIR domain and NF-κB through both its N and C terminal domains (131). The 
activation of these transcription factors leads to the induction of type I IFN, cytokine/chemokine 
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production and dendritic cell maturation, which enables the activation of CTL and NK cells 
leading to a robust antiviral response (130).  
  
Figure 3 TLR3 signaling: TLR3 senses viral dsRNA in endosomal compartments. After binding to dsRNA TLR 
dimerizes and, by its TIR domain, recruits the adaptor molecule TRIF.  TRIF then engages with TRAF3 and, 
through its RHIM domain, also engages with RIPK1 and TRAF6. This interaction leads to two divergent 
downstream signaling pathways, which culminate in either a pro-death (IFN) or pro-survival (NF-kB inflammation) 
response.   
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1.2.2.1 TLR3-IRF3 signaling TRIF is expressed at low levels in cells and after its recruitment to 
activated TLRs, it oligomerizes and forms speckled structures that co-localize with downstream 
signaling molecules (132, 133). It was proposed that the oligomerized TRIF recruits the ubiquitin 
ligase TRAF3 through interactions between the N terminus TIR domain of TRIF (134). The 
autoubiquitination of TRAF3 is then required for the recruitment of TBK1 (TANK-binding 
kinase 1) and IκB kinase-related kinase-ε (IKKε) which are thought to be the main kinases that 
phosphorylate IRF3 in response to viral infection and stimulation of TLR3 (121, 135–137). 
However, there is still no evidence of a direct interaction between TRIF and TRAF3, and it has 
also been shown that in addition to the recruitment of TBK1 through TRAF3, TBK1 can directly 
interact with the N terminal domain of TRIF to activation IRF3 (138). Additionally, it has been 
shown that the cytoplasmic domain of TLR3 is tyrosine-phosphorylated upon activation, which 
recruits PI3K and that this activation is required for the complete phosphorylation and activation 
of IRF3 (139)  
Unlike most of the proteins in the IRF family, IRF3 is constitutively expressed and 
resides in the cytosol in latent form. Upon recruitment of the IRF3 kinases, TBK1 and IKKε to 
the TIRF-TRAF3 complex, specific serine residues in the C-terminal (regulatory) region are 
phosphorylated, IRF3 forms a dimer enabling it to translocate and interact with the co-activators 
CREB-binding protein (CBP) or p300 to form a holocomplex in the nucleus (140–143). This 
holocomplex then binds to interferon-stimulated response elements (ISRE) in the DNA and 
begins transcribing type I interferon and numerous ISGs, including ISG54, ISG56 and ISG60 
inducing a potent antiviral state in infected cells (144). In addition to IFN and ISG induction, 
IRF3 has been suggested to trigger apoptosis in response to activation through a number of 
mechanisms. Recently it was shown that IRF3 contains a BH3 domain, which together with the 
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pro-apoptotic protein Bax, co-translocates to the mitochondria and the results in activation of the 
mitochondrial apoptotic pathway (145). 
1.2.2.2 TLR3-NF-κB signaling In addition to IRF3 signaling, as previously mentioned, NF-κB 
is also activated upon TLR3 stimulation. Under normal physiological conditions, NF-κB is 
sequestered in the cytosol by its interaction with the Inhibitor of κB protein (IκB). In addition to 
recruiting TRAF3 to the TRIF complex, it was also shown that TRAF6 interacts with the N 
terminus of TRIF and is recruited to the speckled signaling structures upon TLR stimulation. It 
was therefore proposed that TRAF6 was required to activate NF-kB signaling, as it has been 
shown that overexpression of a dominate negative TRAF6 or the mutation of TRIF so that it no 
longer interacts with TRAF6, is sufficient to block NF-κΒ signaling (146, 147). It was later 
shown that the TRIF-TRAF6 complex recruits the transforming growth factor activated protein 
kinase 1 (TAK1), a member of the MAP family and TAB2 (146). TAK1 and TAB2 are 
phosphorylated on the membrane, followed by the formation and translocation of TRAF6-
TAK1-TAB2 from the membrane to the cytosol, where this complex then phosphorylates IKKα 
and IKKβ, which in turn phosphorylate IκB, leading to its degradation and nuclear translocation 
of NF-κB (147–149).  
However, the essential role of TRAF6 in TLR3 signaling was later shown to be 
controversial. In follow-up experiments others showed that in cell lines TRAF6 deletion does not 
ablate NF-kB signaling, nor does the deletion of the N terminus of TRIF, which is thought to be 
required from TRAF6 recruitment (134, 150, 151). Upon investigating the activation of NF-kB 
through the C terminus, it was discovered that TRIF also contains a RIP homotypic interaction 
motif (RHIM). It was revealed that rather than recruiting TRAF6, RIPK1 is also recruited to the 
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TRIF complex upon TLR3 stimulation and that its recruitment is required for the degradation of 
IκB and activation of NF-κB (152, 153).    
1.2.2.3 TLR3 expression and function in HNSCC As previously discussed, the main function 
of TLR3 is thought to be the endosomal sensing of viral dsRNA. However, because TLR3 
activation causes IRF3-mediated proapoptotic responses as well as NF-κB-mediated 
inflammatory signals, there has been an interest in investigating the role of TLR3 signaling in 
cancer. Subsequently, TLR3 has been shown to be expressed in many types of cancer tissue 
including HNSCC (154–163). Furthermore, it was recently shown that a TLR3 polymorphism 
(rs5743312) is associated with poor overall survival rates in advanced oral cancer (164). 
Although the molecular consequences this polymorphism have not been elucidated, its effect on 
patient survival demonstrates the significance of TLR3 signaling in HNSCC.   
Several studies have shown that TLR3 expression in HNSCC is associated with anti-
tumor properties and that its activation causes an increase in apoptosis (154–157). It was shown 
that treatment of HNSCC cells with TLR3 ligand induced apoptosis through the down-regulation 
of survivin.(155).  Moreover, we have previously observed that TLR ligand caused an enhanced 
apoptotic response in HNSCC metastatic tumor tissue (156). Additionally, it was shown that 
stimulation of HNSCC cells with TLR3 ligand caused an decrease in cell migration (157). In a 
comprehensive study of the TLR3 signaling in OSCC, He et al. found that poly(I):poly(C) 
stimulated robust responses including upregulated cytokine expression, decreased cell viability, 
suppression of cell proliferation and decreased cell migration (154). 
However, because of its dual role in activating NF-κB, TLR3 expression has also been 
shown to contribute to the metastatic phenotype by enhancing c-MYC-mediated proliferation 
and was shown to be associated with invasive HNSCC (158). Enhanced TLR3 expression in 
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HNSCC patients was significantly correlated with tumors that were poorly differentiated and 
with perineural invasion (159). Moreover, they found that poly(I):poly(C) stimulation promoted 
CCL5-mediated migration in HNSCC cell lines. In addition, a recent proteomic approach 
revealed that TLR3 stimulation of HNSCC cell lines caused a decrease in the expression of 
calreticulin, which inhibits cell proliferation (160, 161) and an increase in profilin-1, which has 
been shown to enhance angiogenesis, ECM invasion and MMP2 secretion (162, 163).  
Because of these conflicting studies, the precise role of TLR3 in the tumor progression of 
HNSCC has not been completely elucidated. Further investigation of the downstream signaling 
molecules that determine the overall cellular response to TLR3 ligand may help explain these 
differing observations.   
1.2.2.4 TLR3 ligand as an immunotherapy for HNSCC Of the TLRs that have been tested as 
potential immunotherapies, it is thought that there is potential for the use of TLR3 ligands for the 
treatment of carcinomas (119). The activation of this pathway with poly(I):poly(C) has shown to 
be a strong inducer of type I IFN and leading to the induction of an adaptive immune response. 
In addition, TLR3-IRF3 activation has been shown to induce apoptosis through a direct 
interaction between phosphorylated IRF3 and the pro-apoptotic protein Bax in infected and 
cancerous cells (145, 155, 156, 165, 166).   
Accumulating in vivo evidence regarding the anticancer role of TLR3 has come from a 
number of studies (95, 167–171). TLR3-/- mice are more prone to breast cancer tumor 
development and progression (95). Using this mouse model it was also shown that there is a 
decreased relapse following dsRNA treatment in TLR3-positive compared to the TLR3-/- breast 
cancers (95, 170). Furthermore, TLR3 ligands have been shown to cause growth arrest and 
apoptosis in prostate cancer cells in a xenograft mouse model (171). Additionally, between 1970 
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and 1990 six random oncology clinical trials were conducted on the efficacy of using dsRNA for 
the treatment of numerous tumor types including gastric, bladder, breast, and melanoma (167–
169). However, the results of these studies were varied, 2 showed a significant clinical benefit 
and 3 showed a more favorable outcome with the administration of dsRNA (95).  
There are currently 23 clinical trials for the use of poly(I):poly(C) as an adjuvant in 
combination with chemotherapies and immunotherapies for treating a number of cancers 
including: colorectal, ovarian, breast, lung, prostate, melanoma, myeloma, leukemia, 
glioblastoma, brain, cervical and liver cancers (172). However, because of limitations in our 
understanding of the molecular mechanisms that dictate the pro-inflammatory (pro-cancer) 
versus pro-interferon (pro-death) and how these pathways may be perturbed in HNSCC, a 
consensus has not been reached as to whether there is any major clinical benefit of this treatment 
(173).  
In addition to TLR3 expression, numerous proteins play a role in defining the 
downstream signaling by mediating the pro-survival NF-κB and pro-apoptotic IFN regulatory 
factor 3 (IRF3) signaling responses to poly(I):poly(C). A better understanding of the mechanism 
of TLR3-mediated apoptosis and its potential involvement in controlling tumor metastasis could 
lead to improvements in current treatment. 
1.2.3 Receptor-interacting protein kinase 1 (RIPK1):  
The kinase RIPK1 belongs to the RIP family of serine threonine kinases that play a role in both 
the innate and adaptive immune responses (174). RIPK1 consists of an N-terminal kinase 
domain, an intermediate domain, a RIP homotypic interaction motif (RHIM), and a C-terminal 
death domain (DD) motif (Figure 4) (46). The intermediate domain of RIPK1 contains a site that 
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is subject to K63-linked ubiquitination (K377), which is recognized by many of the ubiquitin-
binding proteins involved in NF-kB signaling (175). The RHIM domain interacts with multiple 
proteins also containing the RHIM domain such as TRIF, RIPK3 and DNA-dependent activator 
of IRFs (DAI). The six helical bundle, making up the death domain of RIPK1, is also found in 
FAS, TNFR1, FAS-associated death domain protein (FADD and TNFR1-associated death 
domain protein (TRADD) (175, 176).  
 
Figure 4 Schematic representation of the multiple domains of RIPK1. 
 
Because of its multiple domains and interaction motifs, the overall expression levels of 
RIPK1 in a cell have a significant role in defining the outcome of a number of pathways. For 
instance, it was revealed that RIPK1 regulates inflammation signaling (NF-κB activation) in 
response to TNF and TLR ligands, through both kinase-dependent and independent manners 
respectively. Furthermore, RIPK1 has been shown to play a critical role in the necroptotic cell 
death pathway induced by a number of receptors including: TNFα receptor 1 (TNFR1) (177), 
TNFα related apoptosis-inducing ligand receptor (TRAIL) (178), TLR3 and 4 (153, 179, 180), 
and RIG-I (174, 181). However, in the majority of cells, stimulation with these ligands does not 
result in cell death as it was revealed that RIPK1 plays a role in not only contributing to 
necroptosis, but also conversely preventing apoptosis.  
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RIPK1 is probably best known for its canonical role in TNF signaling including its 
function in mediating inflammatory responses, commencing necroptosis and inhibiting 
apoptosis. Upon ligand binding to TNFR1 or TRAIL, these receptors trimerize and recruit a 
membrane-associated complex, named complex I, containing TRADD, RIPK1 and several E3 
ubiquitin ligases including cIAP1 and cIAP2 (46, 182). The recruitment of the ubiquitin ligases 
to the complex leads to RIPK1 polyubiquitination at Lys377 (46). This polyubiquitination begins 
the pro-inflammatory response by recruiting TAB2/3 and TAK1 that activate NF-κB signaling as 
discussed above (46, 182). After internalization of complex 1 a second complex begins to form 
mediated by the recruitment of FADD (182). The downstream signaling pathways that are 
activated now are contingent on the proteins that are recruited to complex II leading to 1) the 
formation of complex IIa via the recruitment of caspase 8 resulting in the induction of apoptosis 
or the recruitment of RIPK3 or 2) the formation of complex IIb and activation of necroptosis 
(182).     
It has widely been accepted, although somewhat controversial (183), that ubiquitination 
of RIPK1 during TNFα signaling contributes to the IκB kinase (IKK)/mitogen-activated protein 
kinase (MAPK)-dependent NF-κB activation that drives inflammatory cytokine production (184, 
185). This suggests a possible mechanism of how RIPK1 can prevent caspase-8-induced 
apoptosis, as it has been shown that NF-kB signaling increases the cellular FLICE-like inhibitor 
protein (cFLIP) levels in response to TNF and TRAIL signaling, and that cFLIP is the inhibitor 
for caspase 8 dimerization (53, 186–188).    
Although RIPK1 is essential in inducing necroptosis through TNFα signaling, its 
expression has been shown to be vital to the survival of the cell. RIPK1 can directly mitigate 
TNF-caspase-8-mediated apoptosis and TLR3-RIPK3-mixed lineage kinase domain-like protein 
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(MLKL) mediated necroptosis (189). Several groups have recently revealed that RIPK1 null 
mice die at birth from systemic inflammation and that the neonatal lethality is caused by 
systemic inflammation from cell death (184, 189–192).  This death can be prevented by also 
deleting RIPK3 and caspase 8, suggesting that RIPK1 acts to directly inhibit these pathways. 
These findings suggest that RIPK1 may limit inflammatory signals by inhibiting TLR3-RIPK3-
MLKL mediated necroptosis in addition to its role promoting NF-kB-mediated inflammation 
(184, 189–192). 
1.2.3.1 The role of RIPK1 in cancer Given the duality of RIPK1 in promoting and limiting 
inflammatory signals as well as preventing and contributing to cell death, it is unsurprising that 
RIPK1 has been found to be both up- and down-regulated in cancers (27, 193–198). Recently it 
was shown that RIPK1 up-regulated and, through the increased activation of the NF-kB 
proinflammatory response, this overexpression contributes to the growth and invasive properties 
in a number of cancers including melanoma, gallbladder, colorectal adenocarcinoma, and non-
small cell lung cancer (193–196). However, RIPK1 expression has also been shown to be down-
regulated in several other types of cancer including breast, OSCC, and colon cancer, as discussed 
below (27, 197, 198). 
The Death Domain of RIPK1 Downregulates EGFR expression 
Upon investigating the expression levels of RIPK1 and EGFR in breast cancer cell lines, 
Ramnarain et al. found that there was a strong correlation between the loss of RIPK1 and the 
overexpression of EGFR (27). With an EGFR-promoter driven luciferase assay, this group 
discovered that the overexpression of RIPK1 by transfection of mouse embryonic fibroblast cells 
(MEFs) increased the levels of EGFR transcription. This finding was surprising given that 
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RIPK1 lacks a DNA binding domain and therefore had not been shown to increase the 
expression of transcription factors necessary for the expression of EGFR. To investigate the 
mechanism these researchers then went on to make mutations in the RIPK1 gene and found that 
the loss of the RIPK1 DD completely ablated the downregulation of EGFR. Examination of the 
EGFR transcription factors revealed that Sp1 forms a complex with RIPK1, interruptible with the 
deletion of the DD, that limits the induction of Sp1 stimulated genes (27).  As EGFR is known to 
be ubiquitously overexpressed in 90% of HNSCC cancers, this finding could suggests a 
mechanism responsible for at least some of the oncogenes high levels (29, 35).  
RIPK1 in DNA damage-induced p53-independent cell death 
In addition to the roles of RIPK1 previously mentioned in prompting cell death through TNF, 
TRAIL and Fas in concert with the accumulation of reactive oxygen species, it was shown that 
RIPK1 is essential for the DNA damage-induced TNFR- and p53-independent cell death 
response (178, 199–201). This study revealed that cell death elicited by the c-Jun N-terminal 
kinase/stress-activated protein kinase pathway is mediated by the activation of JNK by RIPK1 in 
response to DNA damage (200). This finding could have strong implications for the survival of 
cancerous cells in HNSCC as they are often p53 defective (mutations or HPV E7-mediated 
degradation) and have high chromosome instability, as previously discussed.  
Reduction of RIPK1 Expression Increases Resistance to Anoikis 
Anoikis, literally meaning “the state of being without a home,” is a form of cell death that is 
induced by anchorage-dependent cells losing its epithelial cell-matrix interactions (202). This 
form of cell death must be circumvented, therefore, for a cancerous cell to complete the EMT 
transformation and breakaway from the primary tumor site in order to metastasize to distant 
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organs. The detachment of cells from the ECM has been shown to suppress the focal adhesion 
complex (FAK)-mediated survival signaling and, conversely, the overexpression of a 
constitutively active FAK has been shown to rescue cells from anoikis. It was shown that RIPK1 
interacts with both the Fas-mediated anoikis pathway and the FAK-mediated survival pathway 
and that the downregulation or loss of RIPK1 expression causes cells to be sensitive to anoikis 
inducing conditions (203). Later it was shown by the same authors that a sirtuin-3 (SIRT3), a 
nicotinamide adenine dinucleotide-dependent deacetylase that is mitochondrial associated and 
therefore regulates cell death and metabolism, is downregulated by RIPK1 expression and that 
RIP suppression inhibits anoikis induced by SIRT3 (198).     
1.3 RATIONALE AND HYPOTHESIS 
 
HNSCC is the most frequent malignancy of the aerodigestive tract and because of limitations 
with chemotherapy over half of those diagnosed with this cancer succumb to the disease (29). 
Synthetic dsRNA, which act as ligands for the activation of TLR3 and generate IRF3-mediated 
proapoptotic responses in cancer cells, have been used as potent adjuvants to chemotherapy 
(167–169). It has been shown that TLR3 expression and activation in HNSCC is associated with 
up-regulated cytokine expression, decreased cell viability, suppression of cell proliferation and 
decreased cell migration (154–157). However, because of its dual role in activating NF-κB, 
TLR3 expression has also been shown to contribute to metastatic characteristics including 
enhanced proliferation, invasion and migration in HNSCC (158–163). Because of these 
conflicting studies, the precise role of TLR3 in the tumor progression of HNSCC has not been 
39 
completely elucidated. Further investigation of the downstream signaling molecules that 
determine the overall cellular response to TLR3 ligand may help explain these opposing 
conclusions. We postulated that variations in the molecular landscape of HNSCC may tip the 
balance of the TLR3-signaling axis and impact the ultimate cellular response to TLR3 ligand. 
Defining these molecular changes would lead to improvements in the therapeutic use of synthetic 
dsRNA to eliminate cancer cells.  
Using paired cell lines derived from autologous primary and metastatic HNSCC, we 
previously showed that the cells derived from metastatic tumors were unable to activate NF-κB 
while the pro-apoptotic IRF3 signaling remained intact (156). Consequently, stimulation of the 
cells from metastatic tumors with poly(I):poly(C) resulted in an enhanced apoptotic response due 
to the imbalance in downstream signaling (156). As NF-κB activation and activity remained 
intact downstream of other signaling pathways, we postulated that RIPK1, an adapter molecule 
upstream of TLR3-NF-κB signaling, is lost or mutated during tumor progression into metastasis 
(174).  
Taken together, we hypothesized that the RIPK1 expression could be downregulated 
in HNSCC cells and that this reduction contributes to the metastatic phenotype, while 
causing an enhanced apoptotic response to poly(I):poly(C) treatment. In this investigation 
we sought to: 
SPECIFIC AIM 1: Establish the downregulation of RIPK1 expression during the 
tumor progression of HNSCC. Recently it was shown that RIPK1 amplification contributes to 
the growth and invasive properties in number of cancers including melanoma, gallbladder, 
colorectal adenocarcinoma, and non-small cell lung cancer (193–196). However, RIPK1 
expression has also been shown to be down-regulated in several other types of cancer including 
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breast, OSCC, and colon cancer, as discussed below (27, 197, 198). To determine if RIPK1 is 
downregulated during the tumor progression of HNSCC, we will compare the mRNA and 
protein expression between cell lines derived from primary and metastatic tumors.  We will also 
obtain clinical samples from resected patient HNSCC tumors that will be used to validate if the 
downregulation of RIPK1 correlates with disease progression in vivo.    
SPECIFIC AIM 2: Elucidate the mechanistic cause of RIPK1 downregulated 
expression. Moriwaki et al. showed that both RIPK1 and RIPK3 are down-regulated during 
tumor progression of colon cancer and that these genes were suppressed by hypoxia, but not by 
epigenetic DNA modification (197). However, a more recent study showed that RIPK3 is 
downregulated in breast cancer from genomic methylation near its transcriptional start site (204). 
We plan to analyze CpG island methylation data from patient-matched normal and primary 
tissue to determine if changes in RIPK1 downregulation correlates with promoter methylation.  
Additionally, we will culture our metastatic-derived cell lines in hypomethylating conditions to 
determine if a reduction in promoter methylation rescues the expression of RIPK1 in these cells.  
SPECIFIC AIM 3: Investigate the biological consequences of RIPK1 
downregulation in HNSCC tumor progression and elucidate its role in the enhanced 
apoptotic response to poly(I):poly(C). The contribution of downregulated RIPK1 expression to 
tumor progression has been demonstrated in a number of studies, which have revealed an 
increase in the resistance to anoikis, decreased DNA damage-induced p53-independent apoptosis 
and an up-regulation of EGFR expression (27, 197, 198). To elucidate the biological 
consequences of reduced RIPK1 expression, we will make ectopic changes in the expression of 
RIPK1 by restoring the expression of RIPK1 in our metastatic cell lines and silencing RIPK1 
expression in our primary derived cell lines. These cell lines will be used to determine the 
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biological consequences of altered RIPK1 expression in the context of metastatic cell 
characteristics. Finally, they will be used to determine if RIPK1 downregulation is responsible 
for our previously observed enhanced apoptotic response to poly(I):poly(C).       
42 
2.0  MATERIALS AND METHODS 
2.1 CELL LINES AND TISSUES 
The HNSCC cell lines were derived from the primary tumors and metastatic lymph nodes and 
characterized at the University of Pittsburgh as described before (156, 205). The cell lines were 
authenticated within the last six months by HLA typing and STR DNA profiling as described 
before (206), and monitored regularly to be free of mycoplasma contamination. All cell lines 
were cultured in DMEM, (Lonza) containing 10% FBS (Atlanta Biologicals) and 
penicillin/streptomycin (Lonza) at 37°C in a humidified 5% CO2 atmosphere. Pairs of primary 
and metastatic HNSCC tissues were isolated from patients during surgery as per University of 
Pittsburgh IRB-protocol 99-069. Additional cell lines were used in this study (provided in Table 
2). 
 
 
 
 
 
 
43 
Table 2 HNSCC cell lines used in this study 
Cell Line Pri/Met HPV Status p53 Tumorgenicity References 
PCI-6A Primary Negative ? yes (207) 
PCI-6B Metastatic Negative ? yes (207) 
PCI-15A Primary Negative ND, OE, A273C mis yes, 30%  (207, 208) 
PCI-15B Metastatic Negative ND, OE, A273C mis yes, 70%  (207, 208) 
UM-SCC-22A Primary Negative ND, OE, T220C mis yes, 100% (207, 208) 
UM-SCC-22B Metastatic Negative ND, OE, T220C mis no, 0% (207, 208) 
OSC-19-luc Metastatic Negative D,null L164STP Mis/SS yes, 100% (208, 209) 
UMSCC2 Primary Negative WT yes (210, 211) 
UPCI-SCC90 Primary Positive WT yes (212, 213) 
SCC47 Primary  Positive WT yes (212) 
93VU-147T Primary  Positive WT yes (212) 
Note: ND= Non-disruptive mutation, OE = overexpressed, D=disruptive mutation 
2.2 ANTIBODIES AND IMMUNOHISTOCHEMISTRY 
IHC was performed on formalin fixed, paraffin-embedded prospective tissue microarrays 
(0.6mm cores) containing paired primary and metastatic tumors and stained with RIPK1 
antibody (BD Transduction Laboratories). Antibodies against the cleaved PARP were purchased 
from Cell Signaling Technology and actin from Santa Cruz Biotechnology. 
Polyinosinic:polycytidylic acid [p(I):p(C)] (GE Healthcare) was dissolved to a final 
concentration of 1μg/μl in PBS before use. 5-Aza-2′-deoxycytidine was obtained from Sigma. 
2.3 WESTERN BLOTTING ANALYSIS 
To prepare whole cell lysates, cells were washed in ice-cold PBS, scraped and collected in lysis 
buffer (20 mM HEPES pH 7.4, 1 % Triton-X 100, 150 mM NaCl, 1.5 mM MgCl2, 12.5 mM b-
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glycerophosphate, 2 mM EGTA, 10 mM NaF, 2 mM DTT, 1 mM Na3VO4, 1 mM PMSF plus 1x 
protease inhibitors). Protein lysates were quantified using the Quick Start™ Bradford 1x Dye 
Reagent (BioRad). Equal amounts of protein extracts were subjected to 8% SDS–polyacrylamide 
gel electrophoresis and transferred onto a polyvinylidene difluoride membrane. Membranes were 
blocked with 5% nonfat dry milk for twenty minutes and incubated with primary antibody for 1 
hour followed by 3 subsequent 5 minute washes.  After washing, the membrane was covered in 
horseradish peroxidase–conjugated secondary antibody for 1 hour at room temperature. After 
further washing, membranes were treated with 1ml of the Enhanced Chemiluminescence (ECL) 
reagent and exposed onto film and then developed.  
2.4 LENTIVIRAL VECTORS 
Doxycycline inducible lentiviral vectors were generated by performing LR recombination 
between pENTR/D-TOPO FLAG-RIPK1-HA and pInducer 20 destination vector (214). 
Lentiviruses were packaged in 293T and pseudotyped with VSV G protein as before (156). 
Briefly, 2x106 293T cells were seeded in a 10 cm plate and incubated overnight at 37oC. The 
transfection solution was prepared by combining a total of 10µg plasmids (1.2:1:0.8 ratio of gene 
vector, pCMV-Δ8.9 gag/pol and VSV-glycoprotein) with 30µl of lipofectamine2000 in 1ml of 
OPTI-MEM. After 20 minute incubation, the lipo-DNA solution was added dropwise to the 
293T cells. The transfection was allowed to incubate for 24 hours before the media was replaced 
with fresh DMEM. At 48 and 72 hours post-transfection the supernatant was filtered using 
0.45nm syringe filters. Transduction of PCI-15B and OSC-19 cells was carried out overnight at 
37oC in the presence of 1µg/ml polybrene. Cells were selected with 1µg/ml Puromycin to 
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establish stable cell lines.  Similarly, the PCI-15A cells stably expressing shRIPK1 were 
generated by packaging the pLKO-shRNA-RIPK1 plasmid and selecting with 1µg/ml 
Puromycin.  
2.5 QUANTITATIVE PCR ANALYSIS OF GENE EXPRESSION 
Total RNA was purified using TRIzol reagent (Invitrogen) and treated with DNase I (DNA Free 
kit, Ambion). Briefly, the cells were washed with 1XPBS and then 1ml of TRIzol was added 
directly to the well and the cells were incubated for 5 minutes. The TRIzol containing cell lysate 
was then transferred to 1.5ml tubes and 200µl of chloroform was added to the suspension. The 
mixture was then vortexed and centrifuged at 13,000g for 15 minutes at 4oC. The top clear layer 
of the centrifuged sample contained the total RNA and was carefully transferred into new tubes 
containing 500µl of isopropanol. The isopropanol-RNA mixture was incubated for 10 minutes at 
RT to allow the RNA to precipitate out of solution. The RNA was then pelleted by centrifugation 
at 13,000g for 10 minutes at 4oC. The pelleted RNA was then washed with 500µl 75% ethanol 
and re-suspended with 30µl of RNase free water.     
Total RNA (1µg) was used for reverse transcription using iScript cDNA synthesis kit 
(Bio-Rad) and subjected to real-time PCR using a CFX96 real time system (Bio-Rad) according 
to manufacturer’s instructions. Primers for RIPK1 (forward 5’-
CTGGGCTTCACACAGTCTCA-3’ reverse 5’-GTCGATCCTGGAACACTGGT-3’) and 
RPL32 were as previously reported (215). PCR amplification of each gene was normalized to 
that of RPL32. 
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2.6 DNA METHYLTRANSFERASE INHIBITION ASSAY 
Cells were seeded 2x105 per well in 12 well plates. After 24 hours the cells were treated with 0, 
1, 5, 10 or 15 µM 5-Aza-2′-deoxycytidine. The media was changed every 24 hours for 72 hours 
and replaced with fresh 5-Aza-2′-deoxycytidine. After 72 hours incubation, the cells were 
harvested for RT-qPCR and western blot analysis.  
2.7 ANOIKIS-RECOVERY ASSAY 
Twenty-four well plates were coated with 200µl poly-2-hydroxyethyl methacrylate (poly-
HEMA) (10mg/ml) diluted in 75% ethanol three times allowing the reagent to dry before 
reapplying. After the wells had dried, 5x105 cells were plated and incubated in the poly-HEMA 
coated wells for 48 hours. After the 48 hours incubation, the cells were pipetted several times to 
break up aggregates that had formed from growing in suspension conditions and then the cells 
were transferred to 6 well plates for recovery. Cells were recovered for 24 and 96 hours before 
they were fixed with a 50/50 mixture of methanol and water containing 4% crystal violet. Images 
of the stained plates were taken using a pc scanner. 
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2.8 MIGRATION ASSAY 
2.8.1 Two-dimensional wound-healing (scratch) assay.  
PCI-15A-shCTRL and PCI-15A-shRIPK1 were seeded 2x105 cells per well in 12 well plates and 
were incubated until reaching ~100% confluence (24 hours). The cell monolayer was then 
“scratched” once with a p-200 pipet tip causing an approximately 1mm wound in the monolayer. 
Microscopic phase contrast images were taken immediately after, and 12 hours post-wound and 
the migration distance was quantified. 
2.8.2 Three-dimensional transwell migration assay.  
To assay the three-dimension migration of our PCI-15A-shCTRL and PCI-15A-shRIPK1 cell 
lines, cells were seeded in BDbiocoat 8.0 micron fibronectin inserts (pre-coated with Human 
Fibronectin (HFN), which promotes cell attachment) and the number of migrated cells was 
quantified and values normalized to BDbiocoat 8.0 micron control inserts according to the 
manufacturers protocol.  
2.9 ORTHOTOPIC XENOGRAFT MODEL 
Bioluminescence imaging was performed to monitor the time course to metastasis of OSC-19-luc 
tumor cells stably expressing pcDNA3-CTRL or pcDNA3-RIPK1. These cells were harvested 
from subconfluent cultures by trypsinization and, after washing with PBS, 1x105 cells were 
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injected into the lateral tongues of nude mice. The mice were imaged once before tumor 
implantation (day 0). After the implantation of tumor cells the mice were imaged with 
bioluminescence imaging starting on day 4 after implantation and were followed by imaging 1–2 
times per week until day 11. For bioluminescence imaging, the mice were injected 
intraperitoneally with a 150 mg/kg dose of D-luciferin (Biosynth) in phosphate-buffered saline, 
anesthetized with 2.5% isoflurane, and imaged with a charge-coupled device camera–based 
bioluminescence imaging system (IVIS 100; Caliper; exposure time, 1–5 min; binning, 16; field 
of view, 12; f/stop, 1; open filter). Signal was displayed as photons/s/cm2/sr. 
2.10 DATASETS AND STATISTICAL ANALYSIS 
2.10.1 Datasets.  
The Cancer Genome Atlas was used for both datasets in this study (promoter methylation and 
expression)(216). For TCGA expression data, we downloaded level 3 RNAseqV2 data for the 
N=30 patient samples with both normal solid tissue and primary solid tumor. After consolidating 
the RSEM values for RIPK1 and actin from each of these samples into an excel chart, we 
normalized the RSEM value of RIPK1 to that of actin. Similarly, TCGA methylation data was 
downloaded and beta values were consolidated into a spreadsheet according to patient matched 
normal solid tissue and primary solid tumor.  
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2.10.2 Statistical analysis.  
Statistical analyses were carried out using GraphPad Prism. * P < 0.05, ** P < 0.01, *** P < 
0.005 and **** P < 0.001 represent statistical significance by two-tailed paired Student’s t test 
analysis. Wherever applicable, plots show mean with standard error bars. When correlating the 
expression and methylation data, we used the Pearson’s correlation coefficient using an n=20 (df 
= 18) one-tailed test for negative correlation with a critical value of -0.468 
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3.0  AIM 1: ESTABLISH THE DOWNREGULATION OF RIPK1 EXPRESSION 
DURING THE TUMOR PROGRESSION OF HNSCC. 
3.1 INTRODUCTION 
 
While investigating the in vitro efficacy of treating HNSCC cell lines with TLR ligands, we 
previously observed an enhancement of apoptosis in response to poly(I):poly(C) in cells derived 
from metastatic tumors as compared to those derived from autologous primary tumors (156). We 
theorized that there could be several reasons why there was an enhanced apoptosis in the 
metastatic cells. One of the most likely explanations was that there was an altered expression of 
TLR3 in these cells that elicited more pronounced signaling, as the up-regulation of TLR3 
expression has been previously reported to correlate to the efficacy of poly(I):poly(C) in the 
treatment of breast cancers (95). However, when we investigated the mechanistic cause for this 
observation, we found no statistically significant difference in the expression of TLR3 or TRIF 
(156).  As it had been shown that IRF3 signaling is able to both directly and indirectly induce 
apoptosis, we reasoned that there could be an amplification of this signaling arm of the TLR3 
pathway (156). However, when we analyzed IFNβ induction, a transcription factor downstream 
of the IRF3 activation, we again found no significant difference (156).  
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As we did not see a difference in the expression of TLR3 or TRIF, nor the downstream 
activation of IRF3, we reasoned that there could be a difference in the TRIF-RIPK1 mediated 
NF-κB signaling arm of TLR3. Theoretically, a loss in NF-κB signaling would enhance the 
apoptotic response as NF-κB signaling has been shown to induce pro-inflammatory and pro-
survival genes upon activation (217).  After analyzing IL-8 induction, a downstream NF-κB 
stimulated gene, we found that there was induction of its expression in the primary, but not 
metastatic cells in response to TLR3 and TLR4 ligands (156).  Conversely, we observed that 
when we treated these cells with, IL-1β, an alternative NF-κB activating cytokine, we saw that 
there was induction of IL-8 in both cell types (156). Moreover, when we treated the metastatic 
cells with IL-1β there was a degradation of IκBα. The complete ablation of NF-κB signaling (IL-
8 induction) in TLR4 was perplexing, because NF-κB is activated thru MyD88 as well as TRIF 
mediated TLR4-NF-κB activation. However, we believe the complete loss in TLR4-NF-κB 
could be partially explained by the significant reduction of TLR4 receptor expression in the 
metastatic cells causing them to be less sensitive to LPS ligand (156).  Additionally it is 
conceivable that in addition to the defect in the TRIF mediated NF-κB activation, there could 
also be a defect in MyD88 signaling in the HNSCC derived cell lines. 
These data suggested there was a defect in the activation of NF-κB by TLR3 signaling 
and that its activity was intact in RIPK1 independent activation of NF-κB through IL-1β 
signaling. We therefore hypothesized that a defect in NF-κB signaling, known to induce pro-
survival and pro-inflammatory signals, could be responsible for our observed apoptotic response 
in metastatic cells. To evaluate this hypothesis, we treated the cells with poly(I):poly(C) in the 
presence of IL-1β and we found that the alternative induction of NF-kB was sufficient to rescue 
the observed phenotype (156). Additionally through a gain-of-function approach we used Bay11, 
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an inhibitor of prosurvival NF-κB, to treat the primary HNSCC cells and showed that in response 
to dsRNA the primary cell line now had an enhanced apoptosis. We concluded that the 
enhancement of apoptosis could therefore be caused by a defect in NF-κB signaling causing an 
imbalanced TLR3 signaling axis in favor of IRF3 resulting in apoptosis. However, the molecular 
mechanistic explanation for this lack of NF-κB activation by TLR3 signaling in metastatic tumor 
derived cells remained to be uncovered. In the following section we describe the identification of 
RIPK1 as the mediator of this differential TLR3 response.  
3.2 RESULTS 
3.2.1 Downregulation of RIPK1 in metastatic HNSCC cell lines. 
Given the above observation (156), we hypothesized that the adaptor protein RIPK1, which is 
uniquely involved in the NF-κB activation through TLR3 might be involved in this differential 
response. We immunoblotted whole-cell lysates from paired primary (PCI-15A & PCI-6A) and 
matched metastatic tumor derived cell lines (PCI-15B & PCI-6B) and observed that metastatic 
cells showed a marked decrease of RIPK1 protein (Figure 5A). This finding validated previous 
studies which suggested RIPK1 levels are reduced during tumorigenesis as a result of alternative 
mechanisms (27, 198, 200). Additionally, we analyzed the mRNA levels in the autologous pair 
of the tumor-derived HNSCC cell line (PCI-15) and we discovered that mRNA levels of RIPK1 
are also downregulated between metastatic (15B) and primary (15A) cell lines suggesting that 
the downregulation of RIPK1 could occur on the transcriptional level (Figure 5B).  
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Figure 5 Downregulation of RIPK1 in metastatic head and neck cancer cell lines: Whole-cell lysates from 
autologous paired primary (PCI-15A & PCI-6A) and metastatic (PCI-15B & PCI-6B) tumor derived cell lines were 
immunoblotted with anti-RIPK1 and anti-actin antibodies (A). (B) qRT-PCR analysis of RIPK1 mRNA expression 
levels in PCI-15A and PCI-15B total RNA. Following the normalization of each sample with the internal control 
RPL32, RIPK1 mRNA levels are shown as % expression with respect to PCI-15A. Each bar represents mean and 
SD from triplicate samples. 
 
3.2.2 The downregulation of RIPK1 expression in HNSCC correlates with disease 
progression in vivo. 
To validate our in vitro evidence suggesting that RIPK1 protein is downregulated in HNSCC, we 
probed tissue microarrays (TMAs) created from resected primary and metastatic tumors with a 
RIPK1 antibody. Immunohistochemistry (IHC) of these samples showed a decrease in the 
expression of RIPK1 between the primary tumor (left image) and the matched metastatic tumor 
(right image) (Figure 6, upper panel). Quantitative analysis of a number of these IHC images 
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showed a significant decrease in the protein levels of RIPK1 from resected metastatic tumors 
compared to primary tumors (Figure 6, lower graph).   
 
Figure 6 Downregulation of RIPK1 protein expression between metastatic and primary HNSCC resected 
patient-matched tumors: (A) Resected primary (n=90) and metastatic (n=32) tumors from patients with HNSCC 
were mounted and stained with RIPK1 antibody. A representative sample is shown in (A, upper panel) where nuclei 
are stained with hemalun (blue) and the tumor cells are scored for RIPK1 expression levels by a pathologist (A, 
lower graph).  
 
We were able to validate the loss in RIPK1 protein expression in our HNSCC derived 
cell lines using immunohistochemistry on resected patient samples. However, we were unable to 
obtain RNA from these clinical samples.  To validate our mRNA in vitro data and determine if 
there is a loss of RIPK1 mRNA loss during tumorigenesis, we sought to utilize one of the 
publically available online HNSCC datasets. We accessed the Cancer Genome Atlas (TCGA) to 
obtain HNSCC transcriptome data provided for normal and primary paired (from the same 
patient) samples. Here we also observed a reduction in the RIPK1 mRNA expression in these 
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samples (Figure 7). This suggests that RIPK1 expression is not only downregulated during the 
transition between primary tumor and metastatic tumor, but also during the transition between 
normal tissue and primary tumor lesion formation. This finding suggests that RIPK1 may play a 
role in the cellular transition during tumorigenesis as well as tumor progression.   
 
 
Figure 7 Downregulation of RIPK1 mRNA expression between primary tumors and normal tissue from 
HNSCC resected matched-patient tumors: RIPK1 mRNA expression RNAseq2 data in HNSCC patient paired 
normal solid tissue and primary solid tumors (n=30) provided by The Cancer Genome Atlas. This data was provided 
as RNA-Seq gene expression estimation with read mapping uncertainty (RSEM) and the RSEM of RIPK1 was 
normalized to the RSEM of Actin.  
 
Also provided in the TCGA was clinical data on HPV status of the patients. There are 
often overlapping and divergent molecular pathway aberrations between HPV positive and 
negative HNSCCs (29). For example, it has been shown that HPV positive tumors are typically 
TP53 wild type and HPV negative tumors are mainly TP53 mutant (29).  However, in both cases 
the p53 pathway is inactivated, although through the expression of the HPV viral oncogene E6, 
rather than TP53 mutation, in HPV positive tumors (29). Interestingly, there is a more favorable 
prognosis with both HPV positive and TP53 wild type tumors and it has been suggested that 
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HPV-positive tumors form a distinct group within HNSCCs (29). Because of this it is thought 
that there may be different pathways that are altered in these tumors through amplification, 
mutation or downregulation  (29). To determine if there is an etiological distinction in the 
reduction of RIPK1, we segregated the normal and primary samples according to their HPV 
status. We found that there was a significant decrease in the RIPK1 levels in both cases 
irrespective of HPV status (Figure 8).  
 
Figure 8 RIPK1 expression is downregulated in primary tumors irrespective of HPV status: Clinical 
information provided by TCGA on HPV status in patient samples was used to separate the HPV negative (n= 18) 
and HPV positive (n=6) patients. RIPK1 mRNA expression RNAseq2 data was then analyzed between these groups. 
This data was provided as RNA-Seq gene expression estimation with read mapping uncertainty (RSEM) and the 
RSEM of RIPK1 was normalized to the RSEM of Actin.  
3.3 DISCUSSION 
Previously we had observed a defect in NF-κB signaling in metastatic cells in response to TLR3 
ligands, leading to a more pronounced apoptosis in these cells compared to their primary 
counterparts (156). While investigating the defect in NF-kB signaling we analyzed the 
expression of the upstream mediators of this pathway. Here we show that RIPK1 was 
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downregulated at both mRNA and protein levels in the metastatic compared to autologous 
primary cell lines. Because RIPK1 is required for TLR3-mediated pro-survival NF-kB signaling, 
we reasoned that this could explain why we observed an enhanced apoptotic response in 
metastatic cells (27).  
 To validate this finding in vivo we used immunohistochemistry of HNSCC tumor 
microarrays from resected patient primary and metastatic samples. We found that the RIPK1 
protein levels were reduced in the clinical specimens suggesting that this is a finding that can be 
recapitulated in patients as well as in cell lines. This finding also validated the use of our cell 
lines in elucidating the mechanistic defect in RIPK1 and the contributions that a loss of RIPK1 
might have on tumor progression. Although a few studies have suggested that RIPK1 levels are 
downregulated during tumorigenesis, to our knowledge this is the first clinical data showing this 
occurrence in HNSCC (27, 198, 200, 203, 218, 219). 
We also validated our protein data at the mRNA level. Expression profiling data from 
patient samples is provided on cancer databases such as the TCGA. However at the time of this 
study, the only data provided by the TCGA on HNSCC was from normal solid tissue and 
primary solid tumor, and not metastatic tumor samples. Upon analysis of this data for RIPK1 
mRNA expression we found that RIPK1 expression is also reduced during the initial phases of 
tumorigenesis, i.e. normal solid tissue expressed relatively higher levels of RIPK1 mRNA than 
tumor samples. This finding suggests that the initial RIPK1 loss could be contributing to 
tumorigenesis and further down-regulation may increase the tumor progressive capabilities of the 
cancer cells.  
 The loss of RIPK1 expression between normal solid tissue and primary tumor and then 
subsequent loss after primary tumors metastasize, suggests that RIPK1 could act as a tumor 
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suppressor gene. After observing this phenomena we wanted to first determine the mechanistic 
cause contributing to the reduced RIPK1 expression and second what are the consequences on a 
cell phenotype after losing this expression. As the protein and mRNA levels were both lower in 
the metastatic cells, we theorized that the downregulation was probably transcriptionally 
regulated. Additionally as the downregulation of RIPK1 expression in HNSCC correlates with 
disease progression in vivo, we speculated that a reduction of RIPK1 contributes to tumor 
promoting properties.   
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4.0  AIM 2: ELUCIDATE THE MECHANISTIC CAUSE OF RIPK1 
DOWNREGULATED EXPRESSION.  
4.1 INTRODUCTION 
Epigenetic modifications enable cells to control DNA transcription by turning on or off coding 
sequences in order to drive appropriate gene expression. The epigenetic landscape is thus 
continuously modified by extracellular and intracellular factors to maintain homeostasis. 
Aberrant epigenetic modifications can have profound effects on gene expression in a cell and 
that these types of modifications are common during tumorigenesis. DNA promoter methylation 
is one such epigenetic change able to alter gene expression profiles.  
The function of methylation in relation to gene expression was first observed by J. D. 
McGhee and G. D. Ginder in the 1980s (220). These researchers compared the methylation 
status in cells with differential gene expression using restriction enzymes that were specific to 
methylated sites (221). Their work was later validated by treating cells with 5-azacytidine, a 
chemical analog for the nucleoside cytosine, which are integrated into growing DNA strands and 
severely inhibit the action of the DNA methyltransferase enzymes that normally methylate DNA.  
DNA methylation consists of covalent attachments of methyl groups to the 5’ position of 
cytosine residues in CG dinucleotides, which are typically clustered in what are known as “CpG 
islands,” or DNA sequences of ~200 base pairs that are GC rich, often containing greater than 
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50% GC content. The methylated cytosines are also found in “CpG shores” which are within 2kb 
of the vicinity of CpG islands (222). The exact mechanism of promoter methylation in 
controlling gene expression has not been fully elucidated, but it is thought that methylated 
promoters alter the binding affinity of transcription factors.   
As we observed a decrease in both the protein as well as mRNA levels in our autologous 
primary and metastatic HNSCC cell lines, we hypothesized that the downregulation may be at 
the transcriptional level. As it is well-established that abnormal DNA methylation is widespread 
in cancer and plays an important role in oncogenesis, we reasoned that promoter methylation 
may contribute to the RIPK1 downregulation (14). Although other studies have shown that both 
RIPK1 and RIPK3 are down-regulated during tumor progression of colon cancer, it was shown 
that these genes were suppressed by hypoxia, but not by epigenetic DNA modification (197). 
However, in support of the notion that RIPK1 may be down-regulated by promoter methylation, 
it was recently revealed that the mechanistic cause of RIPK3 reduced expression in breast cancer 
is through promoter hypermethylation (204).    
4.2 RESULTS 
4.2.1 There is promoter methylation in a CpG island -868 bases from the transcription 
start site of RIPK1. 
In addition to the mRNA data previously shown, the TCGA database also provides DNA 
methylation status of HNSCC resected normal solid tissue and paired primary solid tumor 
analyzed with the Illumina Infinium HumanMethylation450 platform. After accessing this data 
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from N=30 paired samples, we found that there was an increase in RIPK1 promoter methylation 
(beta value) in the -868 probe position from the RIPK1 transcription start site (Figure 9). We 
included promoter methylation from all of the CpG islands provided for RIPK1 as well as a 
related gene (RIPK2) and a housekeeping gene (ACTN) to show that although alterations in 
promoter methylation may be widespread in tumorigenesis, this method has the sensitivity to 
detect relevant changes in a specific gene.  
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Figure 9 Promoter methylation in a CpG island -868 bases from the transcription start site of RIPK1:  RIPK1 CpG island methylation data from HNSCC 
patient paired normal solid tissue and primary solid tumors (n=30) analyzed with Illumina Infinium HumanMethylation450 was provided on The Cancer Genome 
Atlas (A). Graphic representations of the average beta values in normal vs primary samples for each of the CpG islands are provided (A, right). The beta value is 
the ratio of the methylated probe intensity and the overall intensity and therefore 1.0 (red) relates to higher methylation and 0 (green) to lower methylation.
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4.2.2 Promoter methylation correlates with RIPK1 expression in resected tumor samples. 
As we had obtained mRNA expression (Figure 7) and CpG methylation datasets (Figure 10A) 
from the matched patients, we were able to test the correlation between these two parameters. 
We plotted the difference in RIPK1 promoter methylation (beta value) versus the difference in 
mRNA expression (RNAseq RSEM value) between normal tissue and primary tumors from the 
same patient.  After plotting these data, we used the Pearson’s correlation coefficient with an N 
of 20 as an indicator of correlation. As shown in Figure 10B, we found a strong negative 
correlation between the increases in promoter methylation verses the decrease in RIPK1 
expression.  
 
 
Figure 10 Promoter methylation correlates with RIPK1 expression in tumor samples: The significant 
difference observed the RIPK1 CpG islands -868 from the transcription start site from Fig. 9 was represented here 
more clearly as a box-and-whisker blot (A). (B) Correlation between the changes in methylation status at -868 from 
paired normal and primary samples to the matched change in expression between paired normal and primary 
samples (same patient TCGA methylation vs RNAseq2 data). Statistical values represent Pearson’s correlation 
coefficient using an n=20 (df = 18) one-tailed test for negative correlation with a critical value of -0.468.  
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4.2.3 Hypomethylating treatment conditions restored the expression of RIPK1 in the PCI-
15B metastatic tumor derived cell line. 
To experimentally validate the TCGA correlative data, we treated the HNSCC cell line PCI-15B 
with a hypomethylating reagent. 5-aza-2’-deoxycytidine is a chemical analogue of the cytosine 
nucleoside that causes an inhibition of DNA methyltransferase during DNA replication. 
Treatment of the HNSCC cell line PCI-15B with an increasing dose of 5-aza-2’-deoxycytidine 
should cause a reduction in the levels of promoter methylation. The dose response in Figure 11A 
and Figure 11B shows that the expression of RIPK1 mRNA and protein correlates to the 
increasing concentration of 5-aza-2’-deoxycytidine. 
 
Figure 11 Hypomethylating treatment restored the expression of RIPK1 in PCI-15B Metastatic cells: PCI-15B 
metastatic cells were treated with an increasing concentration of the DNA methyltransferase inhibitor (5-aza-2'-
deoxycytidine) and the mRNA and protein levels were quantitated by qRT-PCR (C) and immunoblotting (D) 
respectively. Bars represent the mean and SD from triplicate readings of the representative blot provided in (D, 
upper panel) 
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4.3 DISCUSSION 
After analyzing the methylation data for HNSCC provided by the TCGA, we found that there 
was an increase in the amount of promoter methylation at a specific CpG island -868 bases 
upstream of the TSS in the RIPK1 promoter region. However, we did not observe any promoter 
methylation in the additional genes we investigated, including RIPK2 and Actin (Figure 9), as 
well as RIPK3 and RIPK4 (data not shown). Thus, we reasoned that this methylation could be 
responsible for the observed downregulation in RIPK1 expression. This postulation was 
supported by our correlative analysis of methylation status and RIPK1 mRNA expression 
profiles that showed a significant association between the increase in methylated promoter and 
the reduction in RIPK1 expression. To our knowledge this is the first study to show an 
association between the downregulation of RIPK1 expression and a change in promoter 
methylation.    
Results obtained through the analysis of TCGA data provided correlative evidence to 
support our hypothesis.  Therefore, to obtain causal evidence, using a model system we treated 
our PCI-15B metastatic cells with a DMT inhibitor, 5-aza-2'-deoxycytidine, and found a 
significant increase in the levels of RIPK1. These data supported our hypothesis that the change 
in promoter methylation may, at least partially, be the mechanistic cause of downregulated 
RIPK1 expression. Though it was recently shown that both RIPK1 and RIPK3 are down-
regulated during tumor progression of colon cancer, it was also shown that the expression was 
suppressed by hypoxia, but not by epigenetic DNA modification (197). However, a more recent 
study showed that RIPK3 is downregulated in breast cancer from genomic methylation near its 
transcriptional start site (204). Our data suggest that promoter methylation could be the 
mechanistic cause of RIPK1 mRNA downregulated during tumor progression. However, the 
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exact mechanism of how this methylated region controls RIPK1 expression remains to be 
determined.  
Based on ChIP-seq results provided by The Encyclopedia of DNA Elements (ENCODE), 
the methylated site that we identified in the RIPK1 promoter is occupied by the transcription 
factor ARID3A in various cell lines. It is therefore possible that the enhanced methylation found 
in tumor cells reduces ARID3A binding to RIPK1 promoter resulting in reduced RIPK1 
transcription. Although ARID3A is known to be involved in transcriptional regulation of various 
genes related to lymphocyte development, it is not clear how DNA-methylation in the ARID3A-
binding site changes its transcriptional ability (223). It is possible that enhanced methylation in 
the RIPK1 promoter found in tumor cells might change its ability to transcribe RIPK1. It is 
notable in this regard that enhanced expression levels of ARID3A is known to provide better 
prognosis for colon cancer (224).  
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5.0  AIM 3: INVESTIGATE THE BIOLOGICAL CONSEQUENCES OF RIPK1 
DOWNREGULATION IN HNSCC: TUMOR PROGRESSION AND ENHANCED 
APOPTOTIC RESPONSE TO POLY(I):POLY(C).  
5.1 INTRODUCTION 
As previously discussed, it has been revealed that despite the role of RIPK1 in promoting 
necroptosis, it is also vital in epithelial cells to mitigate apoptosis in response to a number of 
stimuli (184, 189–192). It seems counterintuitive, therefore, to suggest that RIPK1 acts as a 
suppressor of tumor cell death and that loss of its expression can drive tumorigenesis. However, 
there is an increasing body of evidence that suggests the latter. Thus far, the following three 
publications have reported how a loss in RIPK1 expression can give a growth advantage to 
cancerous cells including 1) overexpression of EGFR (shown to be a vital oncogene in HNSCC), 
2) DNA damage-induced p53-independent cell death, and 3) the induction of anoikis resistance 
(27, 198, 200, 203, 218, 219). As we observed a loss in RIPK1 throughout tumorigenesis and 
tumor progression, we sought to determine if this downregulation could be contributing to these 
characteristics. We hypothesized that silencing of RIPK1 in our primary HNSCC derived cell 
lines would enhance the metastatic phenotype of malignant HNSCC.  
As described before, the acquired ability of a cancer cell to undergo migration and 
invasion into distant metastatic sites is one of the hallmarks of cancer (31, 32). This process 
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contributes to the EMT, whereby it mimics the normal physiological processes of cell movement 
such as embryonic morphogenesis, would healing and immune-cell trafficking (225–227). 
Tumor cell migration is an active process that results from a continuous cycle of the 
interdependent steps polarization, elongation, pseudopod formation and ECM attachment, 
followed by contraction (227). This process is thought to be regulated by the motility-inducing 
chemokines and growth factors that induce and maintain migration by signal transduction 
through PI3K (228). As RIPK1 has been shown to contribute to PI3K signaling through 
upregulated EGFR expression, we hypothesized that RIPK1 silencing may increase the rate of 
migration in the primary derived HNSCC cells. 
RIPK1 downregulation may be advantageous for the primary tumor to develop metastatic 
characteristics as others have suggested. However, because of the role of RIPK1 in activating 
TLR3-NF-κB pro-survival signaling, we sought to determine if the downregulation of RIPK1 
was responsible for the enhanced apoptosis that we previously observed in metastatic HNSCC. 
This would be an exciting finding as it has implications for the use of RIPK1 as a potential 
biomarker for patients whose tumors would be more susceptible to an apoptotic response to 
treatment with TLR3 ligands.  
5.2 RESULTS 
5.2.1 Modulation of RIPK1 expression changes in vitro tumor-promoting properties.  
To define the in vitro consequences of RIPK1 downregulation on cellular properties, we used 
RNA interference to silence RIPK1 expression in the PCI-15A primary tumor derived cell line. 
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Similarly, to examine the role of RIPK1 in the previously observed apoptotic response, we 
created clones stably expressing a RIPK1 construct in PCI-15B, a cell line derived from a 
metastatic tumor. We then analyzed the expression of RIPK1 in these cell lines containing 
ectopic changes and found that there was a restored expression of RIPK1 in the cell line derived 
from a metastatic tumor and, conversely, clones with shRNA knock-down of RIPK1 expression 
had comparable to the expression of RIPK1 in metastatic cells (Figure 12).   
 
 
Figure 12 Ectopic changes in the expression of RIPK1 in primary and metastatic HNSCC derived cell lines: 
After silencing RIPK1 in the primary and restoring the expression of RIPK1 in metastatic derived tumor cell lines, 
we analyzed the expression RIPK1. Untreated lysates from the PCI-15A & B cells with ectopic changes to RIPK1 
levels were immunoblotted for the expression of RIPK1 and Actin.  
 
  We used 2D scratch (Figure 13A) and 3D transwell migration assays (Figure 13B) in 
the PCI-15A shRIPK1 cell line to determine if a loss in the expression of RIPK1 could contribute 
to the abilities of tumor cells to metastasize. We observed that the 2D wound healing was 
significantly more efficient in the PCI-15A shRIPK1 cells than in the shCTRL, indicating that 
decreased RIPK1 expression increases the migration rate of PCI-15A cells. Similarly, when the 
same cell line (PCI-15A-shRIPK1) was used in a 3D migration assay in a transwell chamber, 
there was an enhanced migration of the cells through the fibronectin coated membrane compared 
to the control cell.  
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Figure 13 Silencing of RIPK1 in primary derived HNSCC cell lines enhances the rate of migration: (A) Cell 
migration of PCI-15A primary cell lines stably expressing RIPK1 shRNA in a 2D scratch assay (A). 2D migration 
was quantified as the measured (mm) difference between the scratched gap at 0 hours and at 24 hours (A, lower). 
Cell migration was also measured in these cells using a 3D transwell migration filter assay (B) The left panel 
provides a schematic of the 3D transwell migration assay. In this assay cells were serum starved for 24 hours before 
seeding into transwell, (Right Panel) 3D migration was quantified based on the number of cells that migrated 
through a porous membrane coated with fibronectin.  
 
Anoikis is a form of apoptosis that results from loss of cell adhesion to the ECM (202). 
Thus, anoikis plays an important protective role in preventing actively proliferating cells from re-
attachment and growth in inappropriate environments (229).  Resistance to anoikis is a common 
feature of the carcinoma epithelial-mesenchymal transition and is necessary for transformed cells 
to survive under “anchorage independent” growth conditions (202).  In vivo, anoikis resistance 
would result in loss of apoptotic signals after detachment of keratinocytes from the basement 
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membrane and allow these cells to survive during the migration and invasion into distant organs 
(229). Using an anoikis-resistance assay (Figure 14A) we validated the work on OSCC from 
Kamarajan et al, who showed that RIPK1 downregulation enhances anoikis resistance. We found 
that PCI-15A cells expressing shRNA to RIPK1 were less capable of reattaching and recovering 
after being cultured in an anoikis inducing environment (Figure 14B) (198). These data suggest 
that in addition to previous observations, we found that RIPK1 downregulation may enhance the 
anoikis-resistance characteristics of metastatic tumors.  
 
Figure 14 Silencing of RIPK1 expression enhanced the anoikis resistance: A schematic for the anoikis resistance 
assay that we used is provided (A). In this experiment cells were plated in poly-HEMA coated wells for 48 hours to 
prevent attachment. After 48 hours the cells were collected and transferred to uncoated plates to allow for 
reattachment and recovery. After 24 and 96 hours of recovery the wells were fixed with methanol, stained with 
crystal violet and imaged. (B) PCI-15A shRIPK1 cells were more anoikis-resistant than shRNA control cells.  
 
 
Finally, we also tested the changes in EGFR expression with ectopic changes of RIPK1 
expression to validate the previous study from Ramnarain et al (27). We observed that the 
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expression of EGFR increased in our shRIP1 stable knockdown cells and, conversely, if we 
ectopically expressed RIPK1 there was a significant decrease in the expression of EGFR (Figure 
15).  
 
 
Figure 15 Modulation of RIPK1 expression inversely correlates to the expression of EGFR: Untreated lysates 
from the PCI-15A & B cells with ectopic changes to RIPK1 levels were immunoblotted for the expression of 
RIPK1, EGFR and Actin.  
 
5.2.2 Ectopic expression of RIPK1 in OSC-19 cells in a mouse model. 
Silencing RIPK1 expression in HNSCC cell lines enhanced metastatic phenotypes and 
expression of RIPK1 decreased the expression of EGFR, an important oncogene in HNSCC. We 
hypothesized that if we ectopically expressed RIPK1 in a metastatic cell line it would decrease 
the rate of metastasis in these cells. We were able to obtain a cell line, OSC-19-luciferase, which 
has been used previously in HNSCC orthotopic xenograft mouse models and has been shown to 
metastasize in 70% of mice tested. We validated the reduced expression of RIPK1 and enhanced 
EGFR levels in the OSC-19-luciferase parental cells by comparing the protein levels to our 
characterized PCI-15A/15B cells (Figure 16A).  We found a similar quantity of these proteins 
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the OSC-19 cells as our PCI-15B metastatic cells.  Additionally, we validated the stable 
expression of the RIPK1 construct in these cells by immunoblotting for RIPK1-flag (Figure 
16B). By introducing this cell line into the tongues of nude mice, through intramuscular 
injection, we hypothesized that there would be a significant decrease in the initial rate and/or 
overall metastasis in the cell lines expressing RIPK1. However, when we tested the migration of 
these cells from the initial injection site into the mouse cervical lymph node, we observed no 
difference between the pcDNA3-CTRL expressing and pcDNA-RIPK1 expressing tumors 
(Figure 16C).   
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Figure 16 Stable expression of RIPK1 in the OSC-19-luc HNSCC cell line does not suppress lymph node metastasis in the orthotopic xenograph mouse 
model: (A) Lysates from the OSC-19 and PCI-15A & B cells were immunoblotted for the expression of EGFR and RIPK1. (B) Lysates from the OSC-19-CTRL 
and ODC-19-luc-RIPK1-flag were immunoblotted for Flag expression. (C) OSC-19 metastatic HNSCC cell lines expressing pcDNA3-CTRL or pcDNA-RIPK1 
were injected into the tongues of nude mice and the cervical lymph node metastasis was observed over the next 11 days by imaging with a bioluminescence 
imaging system (IVIS 100).  Cervical lymph node metastasis is indicated by the black arrows. 
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5.2.3 Ectopic changes in RIPK1 expression modulates dsRNA-mediated apoptosis 
Cleaved poly(ADP-ribose) polymerase (c-PARP) was used as a measure of apoptosis in response 
to poly(I):poly(C) treatment in these experiments. PARP is a nuclear protein that functions to 
recognize DNA damage such as single strand breaks and signals for the cell to repair the 
associated damage. During apoptosis the PARP protein is inactivated by caspase 3 cleavage into 
an 89- and 24-kDa fragment which contain the active site and the DNA-binding domain of the 
enzyme, respectively (33). We therefore used an antibody to the 89kDa cleavage product (c-
PARP) as an indicator of caspase 3 activity, which is indicative of apoptosis (33). In the past, we 
validated the use of c-PARP as an indicator of apoptosis in our cell model using both a cell 
viability assay and a 3/7 caspase glo (Promega) and annexinV/propidium iodine staining and 
observed the same enhancement or apoptosis in the metastatic cells (data not shown). However, 
in these experiments we did not use these techniques to validate our results. Additionally, full-
length PARP levels are often used as an internal control to ensure that changes in C-PARP levels 
are not caused by deregulation of the total PARP expression.  However, a caveat of these 
experiments is that we did not measure total PARP.     
As shown in Figure 17A as the concentration of poly(I):poly(C) increases in PCI-15A-
shCTRL cells there is no change in the amount of apoptosis (c-PARP lanes 2-4 vs. lane 1), 
however there is a significant increase in the apoptotic response to poly(I):poly(C) when the 
expression of RIPK1 is knocked-down in these cells with shRNA (c-PARP lanes 6-8 vs. lane 5). 
Similarly in Figure 17B we found that when we restored the expression of RIPK1 in the PCI-
15B metastatic cell line we observed that there was no longer an enhanced apoptotic response to 
poly(I):poly(C) (lanes 5-8 vs. lanes 1-4). In addition, we restored the expression of RIPK1 in a 
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highly metastatic cell line OSC-19 to ensure that our observation was not an artifact of this 
paired cell line (data not shown) and we observed the same phenotype. These data indicate that 
ectopic changes in RIPK1 expression correlate to the hypothesized changes in the apoptotic 
response to poly(I):poly(C) treatment.  
 
Figure 17 Ectopic changes in RIPK1 expression modulates dsRNA-mediated apoptosis: PCI-15A primary cell 
lines were stably transduced with RIPK1 shRNA (A). These cells were treated with increasing amounts of 
poly(I):poly(C) before whole-cell lysates were analyzed by Western blot using antibodies for cleaved PARP and 
actin as a loading control. Additionally RIPK1 expression was restored in PCI-15B metastatic HNSCC cell line by 
transducing with a RIPK1 expression construct (B). 
 
To validate these findings we created PCI-15B metastatic cells expressing RIPK1 under a 
tetracycline-inducible promoter to determine if there was a dose response to poly(I):poly(C) 
treatment (Figure 18). We observed that as we increased the concentration of doxycycline there 
was an increase in the expression of RIPK1 (lanes 3-6 vs. lane 1 and 2) and a correlative 
77 
decrease in the apoptotic response to poly(I):poly(C) (lanes 4 and 5 vs. lane 2). These data 
suggest that the downregulation of RIPK1 could result in an exploitable enhanced apoptotic 
response to TLR3 ligands in metastatic HNSCC. 
 
Figure 18 Induced RIPK1 expression mitigated dsRNA-mediated apoptosis: The PCI-15B metastatic cell line 
were stably transduced with a dox-inducible RIPK1 expression vector. Whole-cell lysates were prepared from cells 
with an increasing concentration of dox in the presence and absence of 50µg/ml poly(I):poly(C). Cleaved PARP 
levels were analyzed (bottom graph) using the ImageJ gel quantification software package normalizing to actin 
levels. Bars represent the mean and SD from triplicate readings of the representative blot provided in (upper panel).    
5.2.4 Additive Apoptotic effect of poly(I):poly(C) cotreatment with HNSCC therapies in 
HNSCC cell lines 
We observed an enhanced apoptotic response in the metastatic HNSCC cell lines treated with 
poly(I):poly(C). Therefore, we hypothesized that cotreatment with poly(I):poly(C) could increase 
the cell death response to the therapeutics cetuximab and cisplatin. We found that there was an 
increase in apoptosis after treatment with either of these drugs in the presence of poly(I):poly(C), 
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as indicated by cleaved PARP in both primary and metastatic cell lines (Figure 19). These 
treatments appeared to have a synergistic effect, as the levels of cleaved PARP after cotreatment 
were more than that expected from combining the levels of apoptosis in individual treatments.     
 
Figure 19 Additive apoptotic effect with polyI:C cotreatments:  PCI-15A (primary) and PCI-15B (metastatic) 
HNSCC cell lines were treated with 25 µg/ml of polyI:C in the presence or absence of 10µg/ml cetuximab or 
10µg/ml Cisplatin for 24 hours before whole-cell lysates were analyzed by Western blot using antibodies for cleaved 
PARP and actin as a loading control. Additionally the PCI-15B cells were treated with an increasing amount of 
polyI:C in the presence of 10µg/ml cetuximab.   
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5.3 DISCUSSION 
We tested the metastatic potential of modulating RIPK1 expression by measuring the growth 
promoting properties in HNSCC.  We found that knockdown of the RIPK1 expression with 
shRNA increases the rate of migration in HNSCC cell lines derived from a primary tumor, 
extending the notion that RIPK1 may act as a suppressor of tumor progression. Thus, our 
findings align with others who have shown RIPK1 expression is reduced during the tumor 
progression (27, 203). Recently it was shown that there is an inverse relationship between RIPK1 
and EGFR expression in breast cancer (27).  We also found that ectopic changes in RIPK1 in our 
HNSCC derived cell lines inversely correlated with the expression of EGFR. It was suggested 
that RIPK1 binds to and sequesters Sp1, a potent EGFR transcription factor, causing a 
downregulation of the expression of EGFR. This may partially explain why RIPK1 expression is 
reduced in the tumor progression of HNSCC as EGFR levels are upregulated in the majority of 
HNSCC tumors. The regulatory role of RIPK1 on EGFR expression may partially explain the 
enhanced rates of migration that we observed after silencing RIPK1 expression in our primary 
derived cell lines.  
In addition, Kamarajan et al. recently revealed that RIPK1 and sirtuin-3 (SIRT3), a NAD-
dependent deacetylase that is known to regulate cell survival, metabolism, and tumorigenesis, 
have an opposite expression profile in OSCC (198). They showed that silencing RIPK1 
expression increased the expression of SIRT3 and resistance to anoikis. Additionally, they 
showed that growing OSCC cells grown in anoikis promoting conditions caused a down-
regulation of RIPK1 (198). Our data validates this study as silencing RIPK1 increased the 
resistance to anoikis in our primary HNSCC derived cell line. However, further investigation is 
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required to conclusively delineate the mechanistic role of RIPK1 in modulating EGFR and 
anoikis resistance in HNSCC.  
We found that when we treated the modified HNSCC cell lines with poly(I):poly(C) there 
was reduced apoptosis in the metastatic cells that ectopically expressed RIPK1 and an increase in 
apoptosis in the primary cells where RIPK1 expression was partially silenced. This finding 
suggested that the loss of RIPK1 expression during tumor progression increases the sensitivity to 
treatment with synthetic TLR3 ligands. We believe that the implications of these findings are 
that RIPK1 expression or promoter methylation can be used as a potential biomarker for the use 
of TLR3 ligands as adjuvants for treating metastatic HNSCC. 
To test the efficacy of TLR3 ligands as potent immuno-adjuvants in metastatic cells, we 
treated the autologous paired cell lines with poly(I):poly(C) in the presence or absence of the 
common HNSCC therapeutics cetuximab or cisplatin. We observed that there was a more than 
additive apoptotic effect when we cotreated both the primary, and more significantly, the 
metastatic cell lines. Together these findings advocate for in vivo studies to evaluate the effects 
of cotreatment on primary cells that have metastasized into lymph tissue. Additionally it would 
be worth investigating the levels of RIPK1 in HNSCC or additional cancer patients who have 
undergone cotreatment with retrospective gene array studies or that are currently being treated 
with poly(I):poly(C).   
Since we observed that a decrease in the expression of RIPK1 in primary cells contributes 
to their metastatic phenotype, we hypothesized that restoring the expression of RIPK1 in 
metastatic cells would decrease their potential to metastasize. As a corollary of this hypothesis, if 
we ectopically expressed RIPK1 in a metastatic cell line, it would decrease the rate of metastasis 
in these cells.  
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Previous studies characterizing HNSCC cells lines in orthotopic murine models of oral 
tongue cancer revealed that there was no observable cervical lymph node metastasis of PCI-15A 
and PCI-15B cells (230). However, we were able to obtain a cell line, OSC-19-luc, which has 
been used in previous studies and has been shown to metastasize in 70% of mice tested (230). As 
we observed similar RIPK1 and EGFR protein quantities in the OSC-19 metastatic cell lines 
relative to PCI-15B cells, we expected that there would be a reduction in the growth promoting 
properties with ectopic RIPK1 expression.  However, a caveat of this experiment is that we did 
not fully characterize these OSC-19-luc-RIPK1 cells in our migration and anoikis resistance 
assays. 
By introducing this cell line into the tongues of nude mice, through intramuscular 
injection, we hypothesized there would be a significant decrease in the initial rate and/or overall 
metastasis in the cell lines expressing RIPK1.  However, we did not observe a significant change 
in the rate of metastasis between control cells and cells expressing RIPK1. This finding was 
surprising, as we were not expecting the control cells to metastasize in all of the mice we tested. 
It is possible that there were technical limitations in these experiments. For example, we injected 
twice as many cells (1x105 in our study versus 5x104) as the study that showed a 70% rate of 
metastasis (230). Also we discovered, through later characterization, that there were differences 
in the expression of luciferase between the control and RIPK1 expressing cells.  Another 
confounding factor is that we did not characterize these cells, and it is plausible that the 
overexpression of RIPK1 in the OSC-19 cells was not sufficient to change their metastatic 
properties. It is likely that there are more chromosome abnormalities enhancing the metastatic 
phenotype of OSC-19 cells in the nude mouse model as they contain a disruptive p53 mutations, 
whereas our PCI-15A/B cell lines express WT p53 (208). Unfortunately, no syngeneic model 
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exists for HNSCC in mice. However, it could be possible to use another carcinogenesis model 
such as a mouse syngeneic prostate cancer model. The advantage of demonstrating this 
phenotype in a mouse model was that we could test the effectiveness of poly(I):poly(C) to 
eliminate metastatic cells that have downregulated RIPK1 expression.   
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6.0  FINAL DISCUSSION 
Detailed understanding of the molecular mechanisms regulating tumor immunity and 
immunosuppression have led to the development of novel cancer immunotherapeutic 
approaches. The early efforts of immunotherapy were focused on enhancing the amplitude and 
responsiveness of effector T cells to target tumor cells by providing antigen for dendritic cell 
cross-presentation (231). However, this therapy had limitations as neoantigen-specific effector T 
cells often become exhausted (232). This exhaustion is attributed to persistent stimulation with 
antigen and the activation of immuno-checkpoints, both of which are crucial for maintaining 
self-tolerance (232). Consequently, the attention of immunotherapy shifted focus to targeting 
these inhibitory immune-checkpoint proteins, cytotoxic T-lymphocyte-associated antigen 4 
(CTLA4) and programmed cell death protein 1 (PD1), which are often overexpressed on 
exhausted T cells (233). However, it has also been reported that the type I IFN response plays a 
central role in the process of immunosuppression by enhancing the maturation, co-stimulatory 
activity and by increasing the capacity of dendritic cells to present neoantigens (104). Therefore, 
the significance of the innate immune signaling pathways in the context of immunotherapeutics 
have attracted attention (234). The immunotherapy focus has thus changed to stress the 
importance of the innate immune receptors, which culminate in the production of IFN and can 
also directly mediate cell death (235). Among the innate immune receptors, because of its ability 
to strongly induce IFN, TLR3 has attracted close attention (95, 167–171).  
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While examining the role of TLR3 signaling in the metastatic progression of HNSCC, we 
found that there was an enhanced apoptosis by poly(I):poly(C) treatment in cells derived from 
metastatic tumors compared to the primary tumor (156). Mechanistically this difference was 
attributed to a defective TLR3-mediated NF-κB activation in metastatic tumor derived cell lines 
(156). We observed that, though IL-1β and TNFα-mediated NF-κB activation remained intact in 
the metastatic cells, there was a significant reduction in the NF-κB activation upon stimulation 
with poly(I):poly(C)  (156). Since RIPK1 is an essential adaptor for TLR3 mediated activation of 
NF-κB and pro-survival signaling, we compared the expression changes of RIPK1 in cell lines 
and tumor samples. Our results suggest that RIPK1 expression is reduced during the tumor 
progression of HNSCC. Considering the classical role of RIPK1 in mediating TNFR signaling, 
our finding of RIPK1 loss in metastatic tumors was both surprising and counterintuitive. 
However, as discussed below, recent findings about the multifunctional roles of RIPK1 help 
reveal a possible explanation of reduced RIPK1 expression during HNSCC tumor progression. 
RIPK1 induces TNFR-mediated necroptosis and, as it has recently been shown that 
TNFR signaling plays a major role in promoting metastasis, it is conceivable that a reduction in 
RIPK1 expression contributes to tumor survival by mitigating this form of cell death (236). 
However, this is unlikely considering that RIPK1 expression is also required to inhibit TNFR-
mediated apoptosis (197). Additionally, in the context of TLR signaling, it has been shown that 
RIPK1 and RIPK3 compete for the RHIM domain in TRIF and that this interaction prevents 
TLR3-RIPK3 mediated necroptosis (55). However, multiple studies have recently emerged that 
provide insights into the role of RIPK1 in mediating these death pathways that may elucidate 
tumor development (184, 192).   
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It was recently shown that RIPK1-null mice die within a few days of birth from systemic 
inflammation, and that the postnatal lethality was not prevented by deletion of RIPK3 or 
caspase-8 (184, 192). However, RIPK1-/-, caspase8-/- and RIPK3-/- triple-knockout mice 
survive into adulthood, affirming the crucial role RIPK1 plays in preventing both TNFα-caspase 
8 mediated apoptosis and TLR3-RIP3 necroptosis (184, 192). Rickard et al. demonstrated that 
the systemic inflammation in RIPK1 null mice was caused by a NF-κB-independent RIPK3-
MLKL necroptotic release of inflammatory signals IL-33 and IL-1α (184). This finding revealed 
that in addition to NF-κB-mediated inflammation, RIPK1 also participates in limiting 
inflammatory signals. As RIPK1 expression is required to prevent TLR3-RIPK3 mediated 
necrosis, reduced RIPK1 expression during the tumor progression of HNSCC may contribute to 
the necrotic release of IL-33 into the tumor microenvironment. The expression of IL-33 has been 
shown to be correlated with poor prognosis in HNSCC, ovarian cancer, breast, lung and gastric 
cancers (237–240). Also IL-33 was recently shown to increase the invasiveness of HNSCC 
(241).  
Furthermore, it is well-established that inflammatory signals released from dying cells 
initiate the adaptive immune response by providing antigen and inflammatory signals for 
dendritic cells which then activate CD8+ T cells through a process called antigen cross-priming. 
As a follow-up to the triple-knockout experiments, Yatim et al. showed that necroptotic, but not 
apoptotic cell death was essential for the effective cross-priming of DCs (219). Moreover, they 
showed that RIPK1-NF-κB activation during necroptosis was required to protect mice from 
tumor challenge (219). In light of these results, it is conceivable that, while RIPK1 
downregulation contributes to TNF and TLR mediated apoptosis and necroptosis respectively, 
the loss of NF-κB signaling in TLR3-RIPK3 mediated necroptosis may prevent the elimination 
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of tumors by the adaptive immune response. However, further investigation is required to 
determine if the reduction in RIPK1 we observed in HNSCC contributions to avoiding immune 
destruction.     
In addition to its crucial role in activating NF-kB signaling, RIPK1 has been identified as 
an essential regulator in determining cell fate in response to several signaling pathways (182). 
Numerous inflammatory cytokines, PAMPs, DAMPs and genotoxic stresses culminate in 
apoptosis and necroptosis mediated by the expression of RIPK1 (182). Among these pathways, it 
was revealed that RIPK1 is required for PARP-1 mediated cell death in response to reactive 
oxygen species and DNA damaged in a p53-independent mechanism (242). This may partially 
explain why it would be advantageous for HNSCC tumors to down-regulate RIPK1 expression 
as mutated p53 and high chromosome instability is observed in the majority of these tumors. 
Furthermore, it was shown that RIPK1 interacts with the CD95/Fas death and focal adhesion 
kinase (FAK) survival signaling pathways to mediate anoikis in oral squamous cell carcinoma 
(OSCC) (203). Therefore, a loss in RIPK1 expression could facilitate the resistance to anoikis, 
enhancing the metastatic potential of HNSCC.    
Given this duality of RIPK1 in promoting and limiting inflammatory signals as well as 
preventing and contributing to cell death, it is unsurprising that RIPK1 has been found to be both 
up- and down-regulated in cancers (27, 193–198). For instance, it was recently shown that 
enhanced expression of RIPK1 is associated with the growth and invasion of human gallbladder 
carcinoma and that the silencing of RIPK1 inhibited the tumor growth of a gallbladder cell line 
in a subcutaneous xenograft mouse model (193). Additionally, RIPK1 expression was shown to 
be increased in human non-small cell lung cancer, contributed to the transformation of human 
bronchial epithelial cells and that RIPK1 expression increased in a cigarette smoke-exposed 
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mouse lung model (194). RIPK1 up-regulation was also shown to contribute to the growth and 
invasive properties in melanoma and colorectal adenocarcinoma (195, 196). However, RIPK1 
expression has been shown to also be down-regulated in several other types of cancer including 
breast, OSCC, and colon cancer (27, 197, 198). 
Our investigation reveals that RIPK1 down-regulation contributes to tumor metastasis in 
HNSCC as RIPK1 silencing in primary derived cell lines enhances the metastatic phenotype. 
These findings align with others who have shown RIPK1 expression is reduced during the tumor 
progression (27, 203). Recently, Ramnarain et al. showed that there is an inverse correlation 
between the RIP1 and the EGFR levels in breast cancer cells (27). Upon further investigation 
they revealed that RIPK1 regulates the expression of EGFR by suppressing Sp1 activity, a potent 
transcription factor for EGFR expression (27). Here we show that ectopic changes in RIPK1 also 
caused an inverse expression of EGFR in HNSCC. Up-regulated EGFR expression may shed 
light to elucidate how reduced RIPK1 expression is advantageous for tumors. The regulatory role 
of RIPK1 on EGFR expression may also partially explain the enhanced rates of migration that 
we observed after silencing RIPK1 expression in our primary derived cell lines. In addition to the 
RIPK1-EGFR inverse relationship, Kamarajan et al. recently revealed that RIPK1 and SIRT3, a 
NAD-dependent deacetylase that is known to regulate cell survival, metabolism, and 
tumorigenesis, have an opposite expression profile in OSCC (198). They showed that silencing 
RIPK1 expression increased the expression of SIRT3 and resistance to anoikis (198). 
Additionally, they showed that growing OSCC cells grown in anoikis promoting conditions 
caused a down-regulation of RIPK1 (198). Our data validates this study as silencing RIPK1 
increased the resistance to anoikis in our primary HNSCC derived cell line. However, further 
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investigation is required to conclusively delineate the mechanistic role of RIPK1 in modulating 
EGFR and anoikis resistance in HNSCC.  
We reconcile the differential findings of RIPK1 up- and down-regulated expression 
during tumor progression given the multiple, often opposing, roles of RIPK1 (27, 193–198). 
RIPK1 expression may enhance cell survival, inflammation and proliferation as well as 
contribute to cell death through necroptosis (190–192, 197, 219). It is conceivable that RIPK1 
contributes to either cell death or survival responses depending on the molecular landscape of the 
tumor including the expression of interacting proteins and presence of signaling molecules in the 
tumor microenvironment. For example, ligands present in the mucosal aerodigestive 
microenvironment may no longer be present in the primary tumor or sterile nodal site of 
metastatic cells. Additionally, it is plausible that the expression of RIPK1 may be altered 
throughout tumor development, as previous reports have demonstrated that RIPK1 is up-
regulated in the early stages of bladder cancer and down-regulated in later stages (243). This may 
explain the observed increase in RIPK1 levels after tumor progression in several of our matched 
patient samples, though the overall RIPK1 expression levels were reduced in HNSCC.  An 
additional confounding factor is that many of these patients have received radiation and chemical 
based treatment and it is conceivable that tumor tissues and the derived cell lines are clonally 
selected for altered RIPK1 expression. For example, it was shown that RIP1 and RIP3 regulate 
radiation-induced programmed necrosis in glioblastoma and therefore the down-regulation of 
these proteins can be associated with radiation resistant cells (244).  
Our methylation data suggests a novel mechanistic cause of the RIPK1 down-regulation. 
We discovered a significant correlation between the reduction of RIPK1 and an increase in 
promoter methylation in a CpG island -868 bases from the transcription start site in matched 
89 
patient samples. We also show that treatment of a metastatic derived cell line with a 
hypomethylating agent rescues the expression of RIPK1. Taken together these data suggests that 
epigenetic changes through promoter methylation may be responsible for the downregulation of 
RIPK1 mRNA transcript during HNSCC tumorigenesis. As previously discussed, the ENCODE 
database ChIP-seq results show that the hypermethylated CpG island in RIPK1 is occupied by 
the transcription factor ARID3A in various cell lines. The hypermethylated region we identified 
may effect ARID3A binding to the promoter resulting in reduced RIPK1 transcription. However, 
there is no data available on the role of promoter methylation and ARID3A activity to support 
this conjecture. Although studies have shown that RIPK1 is downregulated in tumor progression 
this is the first study to our knowledge that proposes a mechanism in HNSCC. It was recently 
shown by Moriwaki et al. that, although RIPK1 and RIPK3 are downregulated in colon cancer, 
the down-regulation was associated with hypoxia rather than hypermethylation (197). We did not 
test for hypoxia driven changes in the expression levels of RIPK1 in our cell lines, but this would 
be interesting as the role of hypoxia in contributing to HNSCC metastasis is well-established 
(151).     
Finally our results show that the reduction of RIPK1 expression during tumorigenesis and 
tumor progression, specifically in cells derived from metastatic tumors, is responsible for the 
enhanced apoptosis by poly(I):poly(C) treatment. In this context, our finding that the expression 
levels of RIPK1 regulates the apoptotic response to poly(I):poly(C), may provide an important 
indicator for its in vivo efficacy. As the downregulation of RIPK1 expression contributes to the 
metastatic tumor progression of HNSCC, but is essential for TLR3-NF-κB survival, we believe 
the results described here may open new prospects for using dsRNA to target metastatic tumor 
cells. In support of this theory, we show that there is a more significant apoptotic effect when we 
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cotreated both the primary, and more significantly, the metastatic cell lines with common 
HNSCC therapeutics cetuximab or cisplatin. These findings suggest that down-regulation or 
promoter methylation of RIPK1 can be used as a potential biomarker for treating patients with 
synthetic poly(I):poly(C).  
In light of using the reduction of RIPK1 expression as an indicator of improved 
chemotherapeutic efficacy, we hypothesize there may be druggable targets to enhance the 
response of patient tumors to poly(I):poly(C). It was recently shown that treatment of breast 
cancer cells with 2-deoxy-d-glucose (2-DG), a glycolysis inhibitor, or 17-
dimethylaminoethylamino-17-demethoxygeldanamycin, an Hsp90 inhibitor, causes a down-
regulation of RIPK1 (245, 246). Interestingly these studies showed that the down-regulation of 
RIPK1 from these treatments increases the apoptotic sensitivity of cells to TRAIL ligand (245, 
246). It may also be possible to target NF-kB activation to enhance the effect of poly(I):poly(C). 
One of the promising NF-κB activation inhibitors, Bortezomib, has been shown to inhibit 
proliferation and directly induce apoptosis in HNSCC (247, 248). It would be interesting to 
reproduce these findings by treating HNSCC cell lines with these therapies in combination with 
poly(I):poly(C).  
In summary, our results suggest that epigenetic changes during tumor progression 
promotes downregulation of RIPK1 expression. This reduced expression enhances the metastatic 
potential of the tumor cell to evade anoikis-induced cell death, and may contribute to tumor 
progression by enhancing the ability of the tumor cell to migrate. Nevertheless, because of the 
dual role RIPK1 plays in augmenting both cell death and survival signaling, these findings could 
suggest a therapeutically exploitable means to provide better efficacy for the poly(I):poly(C) 
adjuvant therapy. This work suggests RIPK1 as a potential candidate tumor suppressor protein 
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and, given the promiscuity of RIPK1 in several additional pathways, provides a new avenue of 
investigation to broaden our understanding of tumor progression of HNSCC. Taken together, our 
results reveal several important aspects of RIPK1 function in the context of tumorigenesis. First, 
our in vivo and in vitro data suggest despite the loss in NF-kB prosurvival signaling, 
downregulation of RIPK1 is correlated with tumor progression. Second, ectopic downregulation 
of RIPK1 enhances metastatic properties of cells, suggesting its crucial function in maintaining 
cellular integrity. Third, the differential levels of RIPK1 in various stages of tumor progression 
may significantly influence the outcome of pro-survival NF-κB signaling, which is prominently 
activated in tumors (247).  
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APPENDIX A: UNIQUE ANTIVITAL ROLES OF THE 2’,5’-OLIGOADENYLATE 
SYNTHETASE ISOZYMES 
Work described in this section was completed by authors Kevin Dylan McCormick,  
Veit Hornung, and Saumendra N. Sarkar and represents a substantial portion of the graduate 
work completed by Kevin McCormick during his graduate studies 
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A.1 INTRODUCTION 
The 2′,5′-oligoadenylate synthetase (OAS) are interferon stimulated genes (ISGs) that interact 
with viral dsRNA present in the cytosol and induce a potent antiviral innate immune response.   
The OAS1-3 genes all contain at least one nucleotidyltransferase domain (NTase), which 
functions as a template-independent RNA polymerase. Upon binding to dsRNA, the OAS1-3 
proteins synthesize 2′,5′-linked oligoadenylates, the second messengers which activate the 
antiviral effector molecule ribonuclease L (RNase L) (249, 250). RNase L binds to the OAS 
synthesized 2′,5′-oligos, dimerizes and then degrades both cellular and viral mRNA, causing an 
inhibition of protein synthesis (250). The RNase L-dependent antiviral role of the human OAS 
isoforms have been shown against several virus families (detailed in Table 3) (251). However, 
recent findings have revealed that OAS may have antiviral properties independent of both the 
NTase enzymatic and RNase L activities. 
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Table 3 Previously reported virus-specific antiviral activity of the OAS family 
Virus OAS1 
(p42,p46, p48) 
OAS2 
(p69/p72)  
 
OAS3 
(p100) 
 
OASL 
(a,b,c,d) 
References 
Reoviridae 
   Rotavirus No OAS isoforms were directly tested 
Rota virus activates and blocks RNase L 
(252) 
Flaviviridae 
   Hepatitis C Virus p46 Inhibits 
p42 and p48 NE  
P69/p72 NE p100 Inhibits a,b Inhibits 
c,b NT 
(253, 254) 
   Dengue Virus  p42 and p46 
Inhibits, p48 NE 
P69/p72 NE p100 Inhibits a,b NE 
c,d NT 
(255–257) 
   West Nile Virus No OAS isoforms were directly tested 
WNV activates and blocks RNase L 
 
Herpesviridae 
   Human cytomegalovirus Inhibits isoform 
unspecified 
NT NT NT (258) 
   Herpes simplex virus No OAS isoforms were directly tested 
RNase L deficiency enhances infection 
(259) 
Picornaviridae 
  Encephalomyocarditis virus NT p69 and p72 
Inhibits 
NT  (260–262) 
      
   Coxsackievirus No OAS isoforms were directly tested against CV,  
however RNase L deficiency enhances infection 
(263, 264) 
Togaviridae 
   Chikungunya NT NT p100 Inhibits NT (265) 
NE = isoform has no effect, NT = not tested 
 
In humans, the OAS family is made up of four genes OAS1, OAS2, OAS3 and OASL 
comprising a total of 10 alternatively spiced gene products OAS1 (p42/p46/p48), OAS2 (p69/ 
p71), OAS3 (p100) and OASL (OASLa-d). The OAS family in mice is more complex and 
contains a total of eight OAS1 isoforms (mOas1a-h), one isoform of mOas2 and mOAS3, and 
two isoforms of mOasL (mOasL1 and mOasL2) Figure 20. Unlike the three isoforms of OAS1 
in humans, which arise from splicing variations generated through alternative splicing, the eight 
mouse OAS1 isoforms were presumably caused through gene duplication events and have 
generated some redundancies (266). The discovery of the numerous OAS repeats has puzzled 
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researchers for some time as there are differences in the antiviral nature of these proteins and 
isoforms that have yet to be explained. Recent findings have revealed that the OAS protein 
family exhibits enzyme-independent antiviral properties in addition to the canonical RNase L 
activity (267). Although it is well-established that human OAS1 has a potent antiviral effect 
against flaviviruses, the severity of infection depends on polymorphism-driven splice-variant 
isoforms (257, 268–273). The difference in OAS1 isoform antiviral activity cannot be explained 
by its enzymatic activity alone as all of the OAS1 isoforms activate RNase L (274).  
 
 
Figure 20 Schematic map showing chromosomal locations of the human and mouse OAS genes: (figure 
adapted from the works from Eskildsen et al. and Kakuta et al. (275, 276)) 
 
Studies have emerged to elucidate the NTase-independent anti-viral mechanisms of 
OAS1.  For example, a splice variant of OAS1, isoform 3 (also known as, p48, or 9-2), was 
shown to contain a Bcl-2 homology 3 (BH3) domain (277). Consequently, upon expression, 
OAS1 interacts with anti-apoptotic proteins Bcl-2 and Bclx(L) to induce apoptosis, presumably, 
in a type-I interferon response mechanism (277). In addition, as OAS1 has been shown to be 
present in the sera of flaviviruses (hepatitis C virus) infected individuals and the levels correlate 
to the success of treating these patients with pegylated IFNα (278, 279), Kristiansen et al. 
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showed that this exogenous OAS1 can protect cells from virus infection (280). They found that 
exogenous OAS1 enters into cells and leads to an antiviral state independently of RNase L or 
IFN induction (280).  
Moreover, it was shown by a number of groups that the virulence of West Nile Virus 
(WNV) in mice is dependent on mOas1b (281–284). More specifically, it was shown that lab 
strains of mice are extremely sensitive to WNV, whereas wild caught mice are resistant (281).  
Through cross breading and genotyping, it was discovered that a premature stop codon in mOas1 
gene in lab mice cause them to be more permissive to WNV infection. This is intriguing as it has 
been shown that the full-length mOas1b lacks a functional NTase domain and is therefore 
enzymatically null. Additionally, it was shown that the difference in WNV infection is not 
dependent on RNase L (285). Thus, an enzyme-independent mechanism must exist for at least 
one of the mOas1 proteins that has been evolutionarily selected for gene duplication.   
To shed light on the RNase L independent antiviral mechanisms of OAS, a recent study 
proposed that the OAS proteins may directly mediate innate immune signaling (286). It was 
shown that OASL, lacks a catalytically active NTase domain and therefore does not activate 
RNase L, but nonetheless contributes to the innate immune antiviral state (286). Remarkably, it 
was shown that the OASL protein contains an ubiquitin-like domain, interacting with both 
dsRNA and RIG-I which circumvents the necessity of RIG-I to be poly-ubiquitinated (286). The 
antiviral mechanism of OASL was therefore suggested to enhance the sensing and downstream 
IFN induction to viral dsRNA.      
We hypothesized that in addition to the NTase-independent role of OASL in RIG-I 
signaling, the additional OAS proteins could be modulating innate immune signaling which 
could explain the enzymatic-independent antiviral effects that others have observed with 
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mOas1b.  While investigating the roles of OAS proteins in innate immune signaling, we found 
that the type-II IFN signaling is defective in the THP-1 OAS1 knock-out cell lines as indicated 
by IRF1 induction. This is an intriguing finding as the importance of IFNγ signaling and IRF1 
induction have been shown to be vital for a robust antiviral response to WNV in vivo (287).  
Additionally, it has been shown that IRF-1 regulates adaptive immune responses as IRF-1-null 
mice show diminished levels of CD8+ T cells in peripheral lymphoid organs, due to decreased 
class I HLA expression and impaired selection in the thymus (287–290).  
A.2 MATERIALS AND METHODS 
A.2.1 CELL LINES
The human monocytic cell line THP-1 and the THP-1 OAS 1, 2 and 3 knockouts were obtained 
from Veit Hornung from the Institute of Clinical Chemistry and Clinical Pharmacology, 
University of Bonn, Bonn, Germany.  
A.2.2 CRISPR/CAS9 KNOCKOUT 
A detailed protocol for the generation of THP-1 knockouts using the CRISPR/Cas9 system has 
been described (291). For the effective knockout of a gene using this system the sgRNAs must 
be selected preferably from the first critical coding regions of the gene of interest. Because the 
THP-1 cells are difficult to transfect, they must either be transduced, or in this case, they were 
electroporated. For electroporation the THP-1 cells were first seeded at a density of 2x105 
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cells/ml and incubated for 24 hours in a 37 degree incubator for 24 hours. After incubation 2x106 
cells are resuspended in 250µl of OPTI-MEM mixed with 2.5µg of the plasmids pCMV-
mCherry-T2A-Cas9 and pLKO.1-sgRNA_OAS1/2/3-CMV-GFP in a 4mm cuvette. The cells are 
then electroporated using an exponential pulse at 250V and 950 uF. The cells are then transferred 
to 6 well plates and allowed to recover for 2 days. These cells are then FACS sorted for mCherry 
positive cells before plating in 96 well –limiting dilution format. Because the electroporation 
efficiency varies between experiments, three different cell densities are chosen for the limiting 
dilutions 200 cells/ml, 100 cells/ml and 50 cells/ml. Sequential 1:1 dilutions of this suspension 
are made and 100µl is plated in the 96 well plates. The clones are grown for two weeks and 
grown clones are picked and re-plated in 96 wells in duplicate; using one well for further 
cultivation and one for subsequent genotyping.    
A.2.3 ANTIBODIES AND REAGENTS 
Antibodies against OAS1 were purchased from Cell Signaling Technology (Beverly, MA) and 
actin from Santa Cruz Biotechnology (cat.# sc-47778 Dallas, TX). Antibodies for phoso-STAT1 
(P-Tyr701) were purchased from Cell signaling (#9171) and total STAT1 from Santa Cruz 
Biotechnology (SC-345 Dallas, TX). IRF1 antibody was also purchased from IRF1 (C-20) Santa 
Cruz Biotechnology (sc-497 Dallas, TX) The IFNγ was purchased from Miltenyi Biotec (130-
096-873).     
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A.2.4 WESTERN BLOTTING ANALYSIS 
To prepare whole cell lysates, cells were washed in ice-cold PBS, scraped, collected in lysis 
buffer (20 mM HEPES pH 7.4, 1 % Triton-X 100, 150 mM NaCl, 1.5 mM MgCl2, 12.5 mM b-
glycerophosphate, 2 mM EGTA, 10 mM NaF, 2 mM DTT, 1 mM Na3VO4, 1 mM PMSF plus 
1x protease inhibitors). Equal amounts of protein extracts were subjected to 8% SDS–
polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane. 
Membrane was blocked with 5% nonfat dry milk and incubated with primary antibody and 
subsequently with horseradish peroxidase–conjugated secondary antibody for 1 hour at room 
temperature. After washing, membranes were exposed onto film and then developed.  
A.2.5 QUANTITATIVE PCR ANALYSIS OF GENE EXPRESSION 
Total RNA was purified using Trizol reagent (Invitrogen) and treated with DNase I (DNA Free 
kit, Ambion, Foster City, CA). Total RNA (1µg) was used for reverse transcription using iScript 
cDNA synthesis kit (Bio-Rad, Hercules, CA) and subjected to real-time PCR using a CFX96 real 
time system (Bio-Rad) according to manufacturer’s instructions. Primers for IRF1 (forward 5’-
CTGGGCTTCACACAGTCTCA-3’ reverse 5’-GTCGATCCTGGAACACTGGT-3’), STAT1 
(forward 5’-CATCCGGTACACTCGCACAG reverse 5’- AAAAGGAGCCAGATCCCAAGA) 
and RPL32 were as previously reported (217).. PCR amplification of each gene was normalized 
to that of RPL32  
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A.2.6 VIRUS INFECTION AND FLOW CYTOMETRY ANALYSIS 
We used a recombinant vesicular stomatitis virus (Indiana strain) encoding full-length enhanced 
green fluorescent protein (eGFP) in frame into the hinge region of the VSV phosphoprotein 
(VSV-GFP) (292). For the VSV-GFP infection, a total of 2x106 THP-1 cells were seeded in 12 
well plates. The cells were treated with 1000 U/ml of IFNγ or IFNα for 18 hours before infection 
with VSV-GFP virus. Aliquots were then taken from the infected wells beginning at the initial 
sign of infection at 4 hours (monitored by fluorescence microscopy), then at 6, 8 and 10 hours 
post-infection. The aliquots containing infected cells were spun down in a microcenTRIFuge for 
5 minutes at 800gs. The cells were washed with 1XPBS and repelleted. After the wash, the cells 
were resuspended in 4% paraformaldehyde for 5 minutes at room temperature. The cells were 
then rewashed and stored at 4 degrees until analyzed by flow. The GFP positive cells were 
quantified using a BD ACCURI C6 Flow Cytometer using the percentage of infection at 0 hours 
PI as a control for baseline.     
A.3 RESULTS 
A.3.1 IFNγ signaling was defective in the THP-1 OAS1 knockout cell lines. 
During our screening of innate immune signaling in THP-1 cells that were OAS1, 2 and 3 
knockout, we found that IFNγ stimulated IRF1 induction was defective in the THP-1 OAS1 and, 
to a lesser extent, the OAS2 knockout cells Figure 21A. This finding was interesting as we 
observed that the response to IFNα was intact in all of the cell clones (data not shown). We used 
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a second clonal isolate of OAS1 knockout to validate the IFNγ-IRF1 result and we also observed 
less induction of IRF1 in these cell lines Figure 21B. To investigate the induction kinetics we 
stimulated these cells with IFNγ during increasing time points and we found that the initial rate 
of IRF1 induction is reduced as well as the peak levels Figure 21C.  
 
Figure 21 Loss of IRF1 induction in OAS1 knockout cell lines in response to IFNγ signaling:  IRF1 induction 
was used to measure response to Type-I interferon stimulation. (A) WT and OAS1, 2 and 3 KO THP-1 cells were 
treated with IFNγ for 8 hours before whole cell lysates were analyzed by western blot. IRF1, was used as a readout 
for IFNγ signaling. (B) The defect in IRF1 induction was validated using an additional OAS1 knockout clone. (C) 
The WT and OAS1 knockout THP-1 cells were treated with 500U/ml of IFNγ for the indicated times. IRF1protein 
production was then quantified by western blotting followed by LiCOR and reported as fold change over Actin.  
 
A.3.2 Downstream mediators of the IFNγ pathway are intact in OAS1 knockout cells.  
To investigate the mechanistic defect in IRF1 induction upon IFNγ stimulation we analyzed the 
total STAT1 induction as well as the phosphorylated STAT1. There was no significant difference 
102 
in the total STAT1 mRNA levels and protein production between the WT and OAS1 KO cells 
(Figure 22A). This is an interesting finding as, in addition to IRF1, STAT1 has also been shown 
to be an IFNγ-stimulated gene and therefore this suggests that there is specificity in the effect of 
OAS1 on IFNγ induced genes and not all the IFNγ stimulated genes were affected. Additionally 
we observed no significant difference in the levels of phosphorylated STAT1 suggesting again 
that the loss of IRF1 induction is downstream of gene expression regulation (Figure 22A). 
Indeed, when we analyzed the mRNA induction of IRF1 there was also no significant difference 
between these cell lines suggesting that the total protein levels are being downregulated by a 
post-transcriptional mechanism (Figure 22B&C).    
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Figure 22 IFNGR downstream mediators are intact in OAS1 knockout cells: WT and OAS1 knockout cells 
were treated with the 1000U/ml of either IFNα or IFNγ for 8 hours and then lysates and mRNA were extracted from 
the cell pellets. (A) Whole-cell lysates were immunoblotted with anti-phosphorylated-STAT1, anti-total STAT1 and 
anti-IRF1 induction. Similarly in (B) the total mRNA was extracted and the levels of STAT1 and IRF1 induction 
were quantified by qRT-PCR.   
A.3.3 Inhibition of the proteasome restores the induction of IRF1 upon IFNγ stimulation 
There are several possible causes of the lack of protein production in the OAS1 KO cells 
including translational regulation. One of the possible causes for the loss of IRF1 protein in 
response to IFNγ in OAS1 KO cells is that there is an enhanced protein degradation of IRF1. To 
test if IRF1 is being degraded in the OAS1 KO cells, we stimulated the WT and OAS1 KO cells 
with IFNγ in the presence or absence of the proteasome inhibitor MG132. MG132 cotreatment 
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resulting in an increased level of IRF1 (~50%) indicating that proteosomal degradation could be 
at least partially responsible for the loss of IRF1 in OAS1 KO cells (Figure 23).  
 
 
Figure 23 IRF1 proteasome degradation rate is increased in the OAS1 knockout cells:  WT and OAS1 KO cells 
were stimulated with IFNγ in the presence or absence of the proteasome inhibitor MG132 for 6 hours before the 
cells were lysed and immunoblotted for the induction of IRF1 and actin.  
A.3.4 Ectopic expression of mOas1b increases IRF1 stability upon IFNγ stimulation 
RAW264.7 cells are derived from BALB/c mice that have been shown to express a truncated 
form of mOas1b, causing them to be sensitive to WNV. The mechanism of this enhanced 
sensitivity has not yet been elucidated. Additionally, it has been demonstrated that IRF1 plays a 
key role in controlling the WNV viral load within an infected mouse (287).  Because of the lack 
of IRF1 induction and stability in THP-1 cells that have OAS1 deleted, we hypothesized that 
restoration of the full length mOas1b in the mouse cells would increase the stability of IRF1. We 
transfected the RAW264.7 cells with plasmids encoding the mOas1b and mOas1g and observed 
that in the presence of cyclohexamide, which blocks global translation, there is an increase in the 
steady-state levels of IRF1 in mOas1b transfected, but not control or mOas1g transfected cells 
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(Figure 24). These results indicate that mice expressing a truncated form of mOas1b may be 
more susceptible to infection because of the loss of IRF1 stability.   
 
 
Figure 24 IRF1 protein stability was increased in RAW cells expressing mOas1b: Raw cells were transfected 
with the indicated plasmids for 48 hours and then treated with 25 U/ml of mouse IFNγ. After 2 hours treatment the 
cells were washed and either left untreated or treated with cycloheximide. After additional 2 hours incubation the 
cells were immunoblotted for mouse IRF1 and actin.  
A.3.5 IFNγ pretreatment of THP-1 OAS1 knockout cells elicited a less protective response 
against VSV-GFP infection.  
As previously mentioned, the mutated from of mOas1b has been shown to be responsible for 
WNV susceptibility in mice and IFNGR and IRF1 knockout mice have also been shown to be 
sensitive to WNV infection.  As we observed a defect in IFNγ signaling in the OAS1 knockout 
cell lines, we wanted to test the antiviral activity in OAS1 knockout cells after priming with 
IFNγ. Because the sensitivity of VSV to IFNγ has been demonstrated in a number of studies, we 
reasoned that it would be a valid system to initially test the antiviral relevance of the defective 
IFNγ signaling in OAS1 knockout cell lines. To this end, we pretreated WT and OAS1 knockout 
cell lines with increasing concentrations of IFNα or IFNγ for 18 hours before infecting with VSV 
at an MOI of 1. Virus production was then monitored at 4, 6, 8 and 10 hours post infection by 
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GFP expression using flow cytometry (Figure 25).  There were less GFP positive cells at 10 
hours post infection in the IFNγ pretreated OAS1 knockout cell lines than in the WT, however as 
expected we observed an equal level of protection in the IFNα in both cell types.    
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Figure 25 IFNγ pretreatment of THP-1 OAS1 KO cells elicited a less protective response against VSV-GFP:  
WT and OAS1 knockout cell lines were treated with 1000U/ml of IFNα or IFNγ for 18h before infecting with VSV-
GFP (Indiana strain) at an MOI of 1. At ten hours post infection, the cells were PFA fixed and % infection was 
reported as the number of cells that were GFP positive quantified by flow cytometry relative to gated total live cells.  
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A.4 DISCUSSION 
The recent discovery that mouse susceptibility to WNV can be traced to a premature stop codon 
mutation in mOaslb, an ortholog of OAS1, is an exciting finding given that this protein lacks an 
enzymatically active NTase domain. This suggests that there could be novel antiviral 
mechanisms for this ISG that are independent of the canonical RNaseL activation, however, the 
molecular mechanism of this antiviral activity has yet to be elucidated.   
We found that the IFNγ induction of IRF1 is defective in human cells that lack the OAS1 
protein. This defect appears to be downstream of IFNγ signaling as there was no significant 
difference in STAT1 phosphorylation and induction or IRF1 mRNA transcription between WT 
and OAS1 knockout cells. This finding suggests that OAS1 was somehow effecting the 
production, stability or degradation of IRF1 protein. When we inhibited proteasome within the 
cells with MG132 and treated the cells with IFNγ, we observed a restoration of IRF1 in the 
OAS1 knockout cells suggesting that OAS1 could be preventing the premature degradation of 
IRF1 by the proteasome. Additionally when we restored the expression of full length mOas1b to 
RAW cells derived from mice with a truncated mOas1b, there was a decrease in the degradation 
of IRF1 upon treatment with the translation inhibitor cyclohexamide indicating that it could be 
responsible for the increased sensitivity to WNV infection. 
We believe that the increased of IRF1 degradation could explain why mice with a 
truncated form of mOasl are more susceptible to WNV as a number of studies have shown that 
both IFNγ and IRF1 are essential to controlling virus infection and dissemination (287). There 
are a number of ways OAS1 could be interfering with the proteasomal degradation of IRF1 
including the regulation the polyubiquitination of IRF1, through interaction of OAS with the E3 
ligase or physical impairment of the E3 ubiquitin ligase to interact with IRF1. Also possible, but 
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less likely as the effect seems IRF1 specific, is the ability of OAS1 to directly interact with the 
proteasome and prevent IRF1 degradation.  In addition, it is possible that the OAS proteins are 
effecting more IFNγ induced genes or, more broadly, that the other OAS isozymes also have 
innate or adaptive immune modulatory activities independent of the enzymatic activity.  
Recently it was discovered that there are polymorphisms in the OAS1 gene that are 
associated with more severe infection with the flaviviruses HCV, dengue and WNV (257, 268–
273). It was later determined that the polymorphisms that are associated with the severe forms of 
these diseases are at exon splicing acceptor sites and that the base changes dictate the OAS1 
isoform message that will be translated (268). These findings suggest that there are differences in 
the antiviral activity of the human OAS1 isoforms, however to date there is no evidence 
suggesting a difference in the RNase L role of these isoforms as they all have NTase activity. We 
hypothesize that there is an isoform-specific effect of OAS1 on IRF1 stability that could be 
responsible for the difference in susceptibility of humans to these viruses. We have cloned the 
three isoforms of OAS1 and we are in the process of restoring the expression of each into the 
THP-1 cells that have OAS1 knocked out to examine this hypothesis.    
Because of the importance of IFNγ signaling and its relationship to IRF1 induction in the 
context of innate as well as adaptive immunity, these findings have implications in not only 
infectious diseases including viruses, bacteria and protozoa as well as non-communicable 
diseases such as cancer. This suggests that the OAS proteins should be investigated more 
rigorously for their involvement in additional enzyme-independent mechanisms. 
 There are many unanswered questions that remain to be addressed from this work. It will 
be interesting to investigate the mechanism of how OAS1 is enhancing the stability or inhibiting 
the degradation of IRF1. There are a number of possibilities including direct interaction between 
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OAS1 and IRF1 that preventing ubiquitination or the interaction with proteins that mediate the 
proteosomal degradation of IRF1. Additionally we would like to validate our model in vivo with 
mOas1b truncated mice to determine if there are decreased levels of IRF1 in response to virus 
and if this is the factor responsible for sensitivity. Finally, it will be interesting to investigate the 
alternatively spiced OAS1 isoforms to determine if the previously observed polymorphism 
associated flavivirus susceptibility/sensitivity is associated with this phenomenon.    
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APPENDIX B: SV40 LARGE T ANTIGEN INDUCTION OF ISGS IS DEPENDENT ON 
THE LT-INITIATED DNA-DAMAGE RESPONSE 
Work described in this section was published in The Journal of Immunology (J Immunol. 2014 
June 15; 192(12): 5933-5942) by authors Adriana Forero, Nicholas S. Giacobbi, Ole V. Gjoerup, 
Kevin D. McCormick, Christopher J. Bakkenist, James M. Pipas, and Saumendra N. Sarkar. 
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B.1 INTRODUCTION 
Upon infection, polyomaviruses (PyV) such as simian virus 40 (SV40) encode for an early 
protein known as Large T antigen that mediates the control of viral DNA replication, host cell 
proliferation and both viral and host gene expression (293). Because of the ability of PyV to 
interfere with the host cell cycle, the viral proteins, especially LT, have been associated with cell 
transformation through its interaction with p53 and pRB (294–296).  The multiple functions of 
LT are determined by its interaction with and manipulation of a number of host proteins and 
pathways, however because of limitations in the knowledge of PyV, the pathogenesis and 
transformative properties of these viruses are not completely understood.   
It has previously been shown that the expression of SV40 LT alone is sufficient to 
activate both the ataxia-telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) DNA-
damage response (DDR) pathways (297). The activation of these DDR pathways act to enhance 
viral genome replication however, at the time this study was published, the cellular consequences 
of this DDR activation had not been fully elucidated.  Additionally it has been shown that SV40 
LT expression can induce a robust interferon response in host cells with the marked induction of 
type I interferon (IFN) and the downstream expression of interferon stimulated genes (ISGs) 
(298).  Here we provide causal evidence that links these two actions whereby the activation of 
DDR through the expression of SV40 LT triggers the stimulation of ISGs.   
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B.2 MATERIALS AND METHODS 
B.2.1 CELLS AND REAGENTS 
BJ/TERT cells and derived cell lines were cultured in DMEM with 20% medium 199 
(Invitrogen, Carlsbad, CA), 10% FBS, and Pen/Strep. The following Abs were used in this study 
for immunoblot analysis: SV LT (pAb 416 and 419) (299), ISG56 (139), and OASL (Abgent, 
San Diego, CA)  (297). 
B.2.2 PLASMIDS AND VIRUS 
Retroviral plasmids pLBNCX and pLBNCX-LT and plasmid pCMV-LT encoding SV40 LT 
cDNA have been previously described (doi: 10.1128/JVI.01515-08, 10.1101/gad.11.9.1098). 
Retroviral vectors pLBNCX and pLBNCX-LT were transfected into (1x107) packaging cell line 
(293-Ampho) using Fugene 6 (Roche, Mannheim, Germany) following manufacturer’s 
guidelines and processed, as previously described (297, 300).  
B.2.3 QUANTITATIVE PCR ANALYSIS OF GENE EXPRESSION 
Total RNA was purified using Trizol reagent (Invitrogen) and treated with DNase I (DNA Free 
kit, Ambion, Foster City, CA). Total RNA (1µg) was used for reverse transcription using iScript 
cDNA synthesis kit (Bio-Rad, Hercules, CA) and subjected to real-time PCR using a CFX96 real 
time system (Bio-Rad) according to manufacturer’s instructions  (297).  
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B.3 RESULTS AND DISCUSSION  
It has previously been reported that deletion of amino acids 89–97 in LT (dl89–97) results in the 
ablation of its binding to Bub1 and a reduction in the activation of DDR by LT (301). To provide 
genetic evidence to support the involvement of LT-mediated DDR in inducing IFNβ, we 
analyzed OASL and ISG60 protein expression in cells stably transduced with either full length 
LT, dl89–97 or vector control (Figure 26A). For dI89–97 mutant expressing cells we used two 
different batches of BJ/TERT cells, which were generated independently at two different times 
(dI89–97(I) and dI89–97(II)). As previously observed, LT expression resulted in a robust 
induction of both ISG60 and OASL expression. However, dl89–97 expression resulted in 
attenuated ISG induction in both cell lines expressing dI89–97 (Figure 26A). The reduction in 
ISG expression was accompanied by diminished IFNβ, ISG60 and OASL mRNA induction in 
dl89–97 expressing cells (Figure 26B) (297). These findings suggest that, even in the absence of 
viral infection, LT induces the DRR mediated IFN response in fibroblast cells.   
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Figure 26 SV40 LT ISG induction is dependent on DDR activation:  (A) Analysis of induction of ISGs by LT 
mutants defective in DDR induction. Lysates were prepared from BJ/TERT cells stably expressing either the wt LT 
or LT dI89-97. Expression of OASL, ISG60, LT, and Actin was detected by immunoblot analysis. (B) Analysis of 
type I IFN and ISG mRNA induction by LT mutant. Total RNA was harvested from BJ/TERT cells expressing LT, 
dI89-97, or empty vector. ISG60, IFNβ, and OASL mRNA expression was determined by qRT-PCR. Expression of 
target genes was normalized to the housekeeping gene RPL32 and reported relative to the enhancement observed 
over empty vector expressing cells (value 1). 
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APPENDIX C: IRF4 REDUCED EXPRESSION INDUCES LYTIC REACTIVATION OF 
KSHV IN PRIMARY EFFUSION LYMPHOMA CELLS 
Work in this section was published in 
Virology (Virology. 2014 June; 0: 4-10.) by Adriana Forero, 
Kevin D. McCormick, Frank J. Jenkins and Saumendra N. Sarkar. 
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C.1 INTRODUCTION 
The long term persistence of Kaposi Sarcoma-associated Herpesvirus (KSHV) has been 
associated with Primary Effusion Lymphoma (PEL) (302). The host-pathogen interactions 
between infected B cells and KSHV that determine the switch between latent and lytic stages of 
the viral replication cycle and the precise mechanism of how KSHV may contribute to 
tumorigenesis have not been fully elucidated.  Specifically, it is known that the interplay between 
host cell innate immune pathways and viruses contribute to the replication cycle and the outcome 
of viral persistence.  
The KSHV replication transactivator (RTA) is a sequence-specific DNA binding protein 
that recognizes and binds to RRE containing viral gene promoters, as well as ISRE and ISRE-
like sequences found in the promoter regulatory regions of cellular ISGs (303, 304). It is thought 
that the transition of KSHV from latency to lytic replication is controlled by RTA, which is 
necessary to initiate gene transcription, virion formation and cell death (303). However the host 
cell signaling pathways that effect the expression of RTA remain elusive.  
Previously, Forero et al. found that the ectopic expression of IRF4 in PEL cells resulted 
in the inhibition of TPA stimulated RTA expression (305). This finding was interesting as IRF4 
expression has been associated with cellular transformation. However it remained to be 
determined if a change in IRF4 expression, through downregulation, would increase the lytic 
virus cycle and result in active virus production. Here we demonstrated that a down-regulation of 
IRF4 expression in PEL cells elicited a robust RTA expression as expected from our previous 
results. This RTA induction yielded a significant increase in the amount of KSHV virions 
produced in the PEL cells.  
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C.2 MATERIALS AND METHODS 
C.2.1 Nuclear Extraction Protocol for the KSHV replication transactivator (RTA) 
expression assay 
BCBL-l stably expressing inducible shCTRL or shIRF4 were seeded in 6 well plates (1x106 
cells/well) in the presence or absence of Dox (100ng/ml). After 24 hours the cells were 
transferred into 15ml conical tubes and pelleted at 300gs for 5 minutes. The supernatant was then 
removed, the cells were suspended in 1ml of 1XPBS and transferred into microcenTRIFuge 
tubes. The cells were then washed with PBS an additional 2X. After washing, the cell pellet was 
re-suspended in 100µl of a hypotonic buffer, pelleted at 1000RPMs and then re-suspended in 
RIPA buffer. The cells were then pulse sonicated for 1 second. After sonication, the cells were 
pelleted at maximum speed for 10 minutes.  The lysates were then immunoblotted for Tubulin, 
DRBP76, IRF4 and RTA.   
C.2.2 Quantitative real-time PCR assay for KSHV production  
BCBL-l stably expressing inducible shCTRL or shIRF4 were seeded in T25 (2x106 cells/flask) 
flasks in the presence (1 sample) or absence (2 samples) of Dox (100ng/ml).  After 72 hours the 
cells were treated with TPA (15ng/ml), co-treated with TPA (15ng/ml) and Dox (100ng/ml) or 
left untreated (mock) as indicated in Figure 27B. After 72 hours incubation with TPA, the 
supernatants containing cells were collected and the cells were pelleted by cenTRIFuging at 
1200RPMs for 10 minutes in 50ml conical tubes. The supernatants were then transferred to 
Beckman SW-28 Ultra-Clear cenTRIFuge tubes (cat# 344058) and the samples were diluted to 
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36ml with 1xPBS to prevent the collapse of the tubes. The samples were then centrifuged , to 
pellet the KSHV, at 12,000rpm for 3 hours using a Beckman Optima L80K cenTRIFuge.  After 
ultra-centrifugation , the supernatant was discarded and the pellet (often invisible) was 
resuspended in 500µl 1xPBS. We then used Ambion’s DNA-free™ DNase treatment (50µl 10X 
buffer and 1µl rDNaseI incubated at 37C for 30 minutes) to remove any intracellular KSHV 
DNA that may have been released during cell pelleting and could have potentially contaminated 
our extracellular virus. We then used the phenol-chloroform technique to denature the KHSV 
and purify the containing DNA. Briefly, we combined equal parts (500µl) phenol-chloroform 
pH=8.0 (Omnipure cat#6680) to our pellets diluted in 1xPBS and after a brief vortexing, we 
centrifuged  the samples for 10 minutes at 14,000g. The top aqueous layer was removed and 
transferred to a new tube containing 1ml 100% ethanol and 50µl 3M sodium acetate (1/10 
original volume). The samples were then incubated overnight at -20oC and then the DNA was 
pelleted by centrifugation  at 14,000g for 15 minutes, the pellets were then washed with 500µl 
70% ethanol and resuspended in 100µl nuclease free water.  To quantify the KSHV DNA, we 
then used the AmpliTaq Gold 360 Master Mix (cat#4398876) according to the manufactures 
instructions with primers and a probe targeting the k8 region of the KSHV genome (real-time 
PCR forward primer 5’-GTC TCT TGG ACA AGC TCG CTG TT-3’, reverse primer 5’-AGT 
GAG CAT GGC AGA TGT TCG T-3’; and probe 5’-FAM-CGG TCT GTG AAA CGG TCA 
TTG ACC TTA C –TAM (as described in Qu et al. 2010)).             
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C.3 RESULTS AND DISCUSSION 
Previously we reported that ectopic expression of IRF4 resulted in the inhibition of TPA-
stimulated RTA (encoded by ORF50) transcription in PEL cells (Forero et al., 2013). To 
determine whether depletion of IRF4 affects RTA expression in PEL cells, we examined RTA 
protein synthesis in Dox (100 ng/ml) treated BCBL-1 sh-IRF4 and observed an increase in the 
nuclear accumulation of RTA (Figure 27). We have now observed that there is an inverse 
relationship between the expression of IRF4 and the expression and downstream activity of 
RTA. Together these finding suggest with that IRF4 plays a role regulating the switch between 
KSHV latency and reactivation.   
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Figure 27 Loss of IRF4 results in a robust induction of KSHV lytic gene expression and viral reactivation: (A) 
Nuclear accumulation of KSHV replication transactivator (RTA) expression follows loss of IRF4. Nuclear fractions 
were prepared from cell treated with Dox for 72 h. Fractions were resolved by SDS-PAGE and immunoblotted with 
antibodies against IRF4, RTA, DRBP76 (nuclear marker), and Tubulin (cytoplasmic marker). (B) KSHV virion 
production following IRF4 silencing. BCBL-1 sh-CTRL and sh-IRF4 cells were stimulated with Dox for 72 h 
followed by stimulation with TPA (15 ng/ml) or Dox and TPA for an additional 72 h. KSHV DNA released into the 
supernatant was measured by probed-based qPCR. Results are expressed as fold change with respect to their 
respective untreated cells (value 1). 
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APPENDIX D: LIST OF ABBREVIATIONS 
Table 4 Table of Abbreviations 
ALT alternative lengthening of telomeres 
ATM ataxia-telangiectasia mutated 
ATR ATM and Rad3-related 
BCBL body-cavity-based lymphoma 
CBP  (cyclic-AMP-responsive-element-binding protein (CREB)-binding 
protein) 
CBP cyclic-AMP-responsive-element-binding protein (CREB)-binding 
protein 
cFLIP Cellular FLICE-like inhibitory protein 
CHX cyclohexamide 
CIN Chromosome Instability  
CLR C-type lectin receptors  
cMET MET Proto-Oncogene Receptor Tyrosine Kinase 
cPARP Cleaved-poly ADP ribose polymerase 
CRT chemoradiotherapy 
CTL cytotoxic T lymphocyte 
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CXCL1 chemokine (C-X-C motif) ligand 1 
DAMPs Damage Associated Molecular Patterns 
DD death domain 
DDR DNA-damage response 
DISC death-inducing signaling complex 
DRBP double-stranded RNA binding protein 
DV Dengue virus 
ECD ectodomain 
ECL Enhanced Chemiluminescence 
ECM Extracellular matrix 
EGFR Epithelial Growth Factor Receptor 
EMCV Encephalomyocarditis virus 
EMT Epithelial–mesenchymal transition 
FADD FAS-associated death domain protein 
FAK focal adhesion complex 
GAGs glycosaminoglycans 
GM-CSF granulocyte/monocyte-colony stimulating factor 
HCV hepatitis C virus 
HFN Human Fibronectin 
HLA human leukocyte antigen 
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HNSCC Head and Neck Squamous Cell Carcinoma 
HPV Human papillomavirus  
IAP inhibitor of apoptosis proteins 
IFN Interferon 
IKKε IκB kinase-related kinase-ε 
IL interleukin 
IRF1 Interferon Regulatory Factor 1 
IRF3 Interferon Regulatory Factor 3 
ISG Interferon Stimulated gene 
ISRE interferon-stimulated response elements 
IκB Inhibitor of κB 
KSHV Kaposi's sarcoma-associated herpesvirus 
KSHV Kaposi Sarcoma-associated Herpesvirus 
LRR leucine-rich repeats 
LT Large T antigen 
MAPK mitogen-activated protein kinase 
MAPK Mitogen-activated protein kinase 
MEFs mouse embryonic fibroblast cells 
MMPs matrix metalloproteases  
MOI Multiplicity of infection 
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NF-κB Nuclear Factor κB 
NK Natural killer cell 
NLR nucleotide-binding oligomerization domain-like receptors 
NTase Nucleotidyltransferase 
OAS 2'-5'-oligoadenylate synthase 
PAMPs Pathogen Associated Molecular Patterns 
PARP poly(ADP-ribose) polymerase 
PCI Pittsburgh Cancer Institute  
PEL Primary Effusion Lymphoma 
PEL Primary Effusion Lymphoma 
PI3K Phosphatidylinositol 3,4,5-Trisphosphate 
PKC Phospholipase C 
Poly(I):poly(C) Polyinosinic:polycytidylic acid 
PRR Pattern Recognition Receptors 
PTEN Phosphatidylinositol 3,4,5-Trisphosphate 3-Phosphatase 
PyV polyomaviruses 
RHIM RIP homotypic interaction motif 
RIPK1 Receptor Interacting Protein Kinase 1 
RLR retinoic acid-inducible gene 1 like receptor 
RNase L ribonuclease L 
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RRE Rev response element 
RTA KSHV replication transactivator 
RTA KSHV replication transactivator 
SCC Squamous cell carcinoma 
SIRT3 sirtuin-3 
STAT1 signal transducer and activator of transcription 1 
TBK1 TANK-binding kinase 1 
TERT Telomerase reverse transcriptase 
TERT Telomerase 
TGFβ Tumor Growth Factor β 
TIR Toll-IL-1 receptor 
TLR Toll Like Receptor 
TNF Tumor Necrosis Factor 
TPA Tissue plasminogen activator 
TRADD TNFR1-associated death domain protein 
TRAIL TNFα related apoptosis-inducing ligand receptor 
TRI signaling type I receptor 
TRIF TIR domain-containing adaptor 
TRII TGFB binding type II receptor  
UMSCC University of Michigan SCC 
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VEGF Vascular Growth Factor Receptor 
WNV West Nile virus 
β2m beta2-microglobulin 
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